

A Universal Isocyanide for diverse Heterocycle syntheses.

¹ Pravin Patil, ¹ Kareem Khoury², Eberhardt Herdtweck,³ Alexander Dömling^{1*}

¹ Department of Drug Design, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands.

² Carmolex Inc, Pittsburgh, Pennsylvania 15213, United States.

³ Technische Universität München, Garching, Germany.

a.s.s.domling@rug.nl

Supporting Information	S-1
General Methods	S-2
General experimental procedure for Ugi-tetrazoles	S-2
General experimental procedure for cyclization	S-3
Computational Chemical Descriptors	S-30
Xray-Crystallographic Information	S-33
Characterization of Products (MS, ¹ H NMR and ¹³ C NMR spectra of compounds)	S-45

Experimental section

1. General methods

Nuclear magnetic resonance spectra (NMR) were recorded on a Bruker Avance 500 spectrometer (^1H NMR (500 MHz), ^{13}C NMR (126 MHz)). Chemical shifts for ^1H NMR were reported as δ values and coupling constants were in hertz (Hz). The following abbreviations were used for spin multiplicity: s = singlet, d = doublet, t = triplet, dd = double doublet, m = multiplet, bs = broad singlet. Chemical shifts for ^{13}C NMR reported in ppm relative to the solvent peak. Thin layer chromatography was performed on Fluka precoated silica gel plates (0.20 mm thick, particle size 25 μm). Flash chromatography was performed on a Teledyne ISCO Combiflash Rf, using RediSep Rf Normal-phase Silica Flash Columns (Silica Gel 60 \AA , 230 - 400 mesh). Reagents were available from commercial suppliers and used without any purification unless otherwise noted. All isocyanides were made in house by either performing the Hoffman or Ugi procedure. Other reagents were purchased from Sigma Aldrich, ABCR, Acros and AK Scientific and were used without further purification. Mass spectra (HRMS) were recorded on an Orbitrap XL (Thermo Fisher Scientific; ESI pos. mode, resolution of 60000@m/z 400). Electrospray ionization mass spectra (ESI-MS) were recorded on a Waters Investigator Semi-prep 15 SFC-MS instrument.

Synthetic procedure A (Ugi reaction):

To a 1 M solution of aldehyde in methanol were added successively 1.0 equiv of amine, 1.0 equiv of azidotrimethylsilane, and 1.0 equiv of isocyanoacetaldehydedimethylacetal. The resulting mixture was stirred at room temperature for 18 hrs. The solvent was removed under reduced pressure and the residue was purified using flash chromatography to obtain the Ugi-product.

Synthetic procedure B (cyclization):

To a solution of Ugi-tetrazole (1 mmol) was stirred with methanesulfonic acid (100 mmol) at room temperature for 18 hours. The reaction was diluted with dichloromethane and quenched with saturated sodium bicarbonate solution at 0-5 $^{\circ}\text{C}$ and extracted with dichloromethane (20 mL x 3). The solvent was removed under reduced pressure, and the residue was purified by flash column chromatography to afford cyclic product.


Synthetic procedure C (Pictet–Spengler cyclization):

To a solution of Ugi-tetrazole(1 mmol) was stirred with methanesulfonic acid (100mmol) at room temperature for 18 hours. The reaction was quenched with saturated sodium carbonate and extracted with EtOAc (20 mL x3). The solvent was removed under reduced pressure, and the residue was purified by crystallization or flash column chromatography to afford cyclic product.

In all the cases, the spectral data are given for the major diastereomer.

8a: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(4-nitrophenyl)methyl)-2-(4-methoxyphenyl)ethanamine.


The product was obtained using procedure **A**, 814 mg, 92 % as pale yellow



liquid; HRMS (ESI) m/z calcd for $C_{21}H_{27}N_6O_5$ $[M+H]^+$: 443.2037; found: 443.20361; 1H NMR (500 MHz, $CDCl_3$) δ 8.19 (d, $J = 8.6$ Hz, 2H), 7.52 (d, $J = 8.6$ Hz, 2H), 7.07 (d, $J = 8.5$ Hz, 2H), 6.82 (d, $J = 8.5$ Hz, 2H), 5.38 (s, 1H), 4.61 (t, $J = 5.4$ Hz, 1H), 4.43 (dd, $J = 14.1, 5.0$ Hz, 1H), 4.34 (dd, $J = 14.1, 5.0$ Hz, 1H), 3.78 (s, 3H), 3.36 (s, 3H), 3.28 (s, 3H), 2.84 – 2.69 (m, 4H), 2.08 (brs, 1H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 158.1, 155.6, 147.6, 145.0, 131.0, 129.5, 128.6, 123.8, 113.8, 102.6, 56.3, 55.7, 55.5, 55.1, 49.2, 48.9, 35.1.

2a: 7-(4-methoxyphenethyl)-8-(4-nitrophenyl)-7,8-dihydro-7H-tetrazolo[1,5-a]pyrazine.


The product was obtained using procedure **B**, 230 mg, 61 % as brown liquid;



HRMS (ESI) m/z calcd for $C_{19}H_{19}N_6O_3$ $[M+H]^+$: 379.1513; found: 379.1514; 1H NMR (500 MHz, $CDCl_3$) δ 8.21 (d, $J = 8.6$ Hz, 2H), 7.52 (d, $J = 8.6$ Hz, 2H), 6.97 (d, $J = 8.4$ Hz, 2H), 6.79 (d, $J = 8.4$ Hz, 2H), 6.59 (d, $J = 5.6$ Hz, 1H), 6.19 (d, $J = 5.6$ Hz, 1H), 6.03 (s, 1H), 3.78 (s, 3H), 3.43 (dt, $J = 14.1, 6.9$ Hz, 1H), 3.35 – 3.23 (m, 1H), 2.87 – 2.78 (m, 2H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 158.5, 148.1, 145.0, 144.2, 129.5, 129.1, 127.9, 127.6, 124.3, 114.2, 95.3, 58.0, 55.2, 54.7, 34.1.


8b: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(4-nitrophenyl)methyl)propan-1-amine.

The product was obtained using procedure **A**, 483 mg, 69 % as pale yellow liquid; HRMS (ESI) m/z calcd for $C_{15}H_{23}N_6O_4$ $[M+H]^+$: 351.1775; found: 351.1775; 1H NMR (500 MHz, $CDCl_3$) δ 8.23 (d, $J = 8.7$ Hz, 2H), 7.61 (d, $J = 8.7$ Hz, 2H), 5.38 (s, 1H), 4.66 (t, $J = 5.4$ Hz, 1H), 4.50 (dd, 1H), 4.39 (dd, $J = 14.1, 5.1$ Hz, 1H), 3.41 (s, 3H), 3.32 (s, 3H), 2.52 (t, $J = 7.1$ Hz, 2H), 1.57 – 1.49 (m, 2H), 0.92 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 155.9, 147.8, 145.3, 128.7, 124.2, 123.9, 103.0, 102.6, 56.6, 49.7, 23.0, 11.6.




2b: 8-(4-nitrophenyl)-7-propyl-7,8-dihydro-tetrazolo[1,5-a]pyrazine.

The product was obtained using procedure **B**, 125 mg, 44 % as brown liquid; HRMS (ESI) m/z calcd for $C_{13}H_{15}N_6O_2$ $[M+H]^+$: 287.1251; found: 287.1251; 1H NMR (500 MHz, $CDCl_3$) δ 8.24 (d, $J = 8.6$ Hz, 2H), 7.61 (d, $J = 8.6$ Hz, 2H), 6.64 (d, $J = 5.7$ Hz, 1H), 6.35 (d, $J = 5.7$ Hz, 1H), 6.25 (s, 1H), 3.18 – 3.05 (m, 2H), 1.72 – 1.56 (m, 2H), 0.91 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 148.3, 145.1, 144.2, 128.2, 127.7, 124.4, 95.0, 57.8, 54.8, 21.3, 10.9.



8c: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(4-methoxyphenyl)methyl)propan-1-amine.


The product was obtained using procedure **A**, 469 mg, 70 % as yellow liquid; HRMS (ESI) m/z calcd for $C_{16}H_{26}N_6O_3$ $[M+H]^+$: 336.2030; found: 336.2029; 1H NMR (500 MHz, $CDCl_3$) δ 7.26 (d, $J = 8.5$ Hz, 2H), 6.88 (d, $J = 8.5$ Hz, 2H), 5.23 (s, 1H), 4.58 (t, $J = 5.5$ Hz, 1H), 4.41 (dd, $J = 14.2, 5.5$ Hz, 1H), 4.23 (dd, $J = 14.2, 6.0$ Hz, 1H), 3.79 (s, 3H), 3.36 (s,



3H), 3.33 (s, 3H), 2.53 (t, $J = 7.4$ Hz, 2H), 1.58 – 1.49 (m, 2H), 0.91 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 159.5, 156.9, 130.2, 128.7, 114.3, 102.6, 56.7, 55.5, 55.3, 49.6, 48.9, 23.0, 11.7.

2c: 8-(4-methoxyphenyl)-7-propyl-7,8-dihydro-tetrazolo[1,5-a]pyrazine.

The product was obtained using procedure **B**, 57 mg, 21 % as brown liquid;



HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{17}\text{N}_5\text{O}$ $[\text{M}+\text{H}]^+$: 272.1512; found: 272.1524; ^1H NMR (500 MHz, CDCl_3) δ 7.27 (d, $J = 8.5$ Hz, 2H), 6.87 (d, $J = 8.5$ Hz, 2H), 6.55 (d, $J = 5.7$ Hz, 1H), 6.26 (d, $J = 5.7$ Hz, 1H), 6.02 (s, 1H), 3.78 (s, 3H), 3.12 – 3.06 (m, 1H), 3.04 – 2.98 (m, 1H), 1.66 – 1.50 (m, 2H), 0.88 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 160.1, 146.3, 130.0, 128.6, 127.9, 114.4, 93.9, 57.7, 55.2, 54.1, 21.1, 10.9.


8d: N-(1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)cyclohexyl)aniline.

The product was obtained using procedure **A**, 509mg, 77 % as white solid, m.p.:

100-102 °C; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{26}\text{N}_5\text{O}_2$ $[\text{M}+\text{H}]^+$: 332.2081; found: 332.2081; ^1H NMR (500 MHz, CDCl_3) δ 7.06 (t, $J = 7.8$ Hz, 2H), 6.73 (t, $J = 7.4$ Hz, 1H), 6.22 (d, $J = 8.4$ Hz, 2H), 4.76 (t, $J = 5.6$ Hz, 1H), 4.64 (d, $J = 5.6$ Hz, 2H), 4.10 (s, 1H), 3.30 (s, 6H), 2.37 – 2.30 (m, 2H), 2.23 – 2.14 (m, 2H), 1.74 – 1.67 (m, 3H), 1.58 – 1.36 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 159.7, 143.8, 129.4, 119.2, 115.1, 103.0, 55.5, 54.2, 50.0, 34.2, 24.8, 21.0.

2d: 7'-phenyl-7'H-spiro[cyclohexane-1,8'-tetrazolo[1,5-a]pyrazine].

The product was obtained using procedure **B**, 195 mg, 73 % as white solid, m.p.:




99-101 °C; HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{18}\text{N}_5$ $[\text{M}+\text{H}]^+$: 268.1557; found: 268.1556; ^1H NMR (500 MHz, CDCl_3) δ 7.44 – 7.35 (m, 3H), 7.24 – 7.20 (m, 2H), 6.76 (d, $J = 5.6$ Hz, 1H), 6.27 (d, $J = 5.6$ Hz, 1H), 2.34 (d, $J = 12.4$ Hz, 2H), 2.02 – 1.91 (m,

2H), 1.73 – 1.54 (m, 5H), 1.10 – 0.98 (m, 1H); ^{13}C NMR (126 MHz, CDCl_3) δ 148.9, 142.1, 130.3, 129.2, 128.9, 127.9, 97.2, 61.0, 33.1, 24.9, 22.3.

8e: N-(1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)cyclohexyl)-2,4-dimethyl aniline.

The product was obtained using procedure A, 604mg, 84 % as white solid; m.p.:


106-108 °C; HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{30}\text{N}_5\text{O}_2$ $[\text{M}+\text{H}]^+$: 360.2394; found: 360.2394; ^1H NMR (500 MHz, CDCl_3) δ 6.91 (s, 1H), 6.64 (d, $J = 8.2$ Hz, 1H), 5.64 (d, $J = 8.2$ Hz, 1H), 4.75 – 4.70 (m, 1H), 4.62 (d, $J = 5.6$ Hz, 2H), 3.96 (s, 1H), 3.30 (s, 6H), 2.41 (d, $J = 13.7$ Hz, 2H), 2.24 (s, 3H), 2.21 – 2.10 (m, 5H), 1.78 – 1.65 (m, 3H), 1.53 – 1.36 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 160.0, 139.2, 131.6, 127.9, 127.4, 123.0, 112.8, 103.0, 55.5, 54.2, 49.9, 34.1, 24.9, 21.1, 20.2, 17.6.



2e: 7'-(2,4-dimethylphenyl)-7'H-spiro[cyclohexane-1,8'-tetrazolo[1,5-a]pyrazine].


The product was obtained using procedure B, 207 mg, 70 % as white solid, m.p.:

148-150 °C; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{22}\text{N}_5$ $[\text{M}+\text{H}]^+$: 296.1868; found: 296.1869; ^1H NMR (500 MHz, CDCl_3) δ 7.16 (d, $J = 8.0$ Hz, 1H), 7.07 (s, 1H), 7.04 (d, $J = 8.0$ Hz, 1H), 6.80 (d, $J = 5.4$ Hz, 1H), 6.08 (d, $J = 5.4$ Hz, 1H), 2.53 – 2.39 (m, 2H), 2.34 (s, 3H), 2.22 – 2.16 (m, 1H), 2.04 (s, 3H), 1.76 – 1.32 (m, 6H), 1.15 – 1.05 (m, 1H); ^{13}C NMR (126 MHz, CDCl_3) δ 148.7, 138.4, 138.3, 138.2, 132.0, 130.6, 128.3, 127.4, 97.4, 61.0, 33.4, 32.4, 25.0, 22.5, 21.9, 20.9, 18.1.



8f: N-(1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)cyclohexyl)-2,6-dimethylaniline.


The product was obtained using procedure **A**, 158 mg, 22 % as white solid, m.p.: 122-124 °C; HRMS (ESI) m/z calcd for C₁₉H₃₀N₅O₂



[M+H]⁺ : 360.2394; found: 360.2393; ¹H NMR (500 MHz, CDCl₃) δ 6.94 (d, *J* = 7.4 Hz, 2H), 6.85 – 6.82 (m, 1H), 5.05 (t, *J* = 5.7 Hz, 1H), 4.78 (d, *J* = 5.7 Hz, 2H), 3.43 (s, 6H), 2.42 – 2.34 (m, 2H), 1.89 (s, 6H), 1.82 – 1.73 (m, 2H), 1.64 – 1.53 (m, 5H), 1.44 – 1.36 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 160.0, 141.9, 131.1, 129.2, 123.0, 103.3, 56.5, 55.9, 51.0, 37.1, 23.0, 22.0, 19.5.

2f: 7'-(2,6-dimethylphenyl)-7'H-spiro[cyclohexane-1,8'-tetrazolo[1,5-a]pyrazine].


The product was obtained using procedure **B**, 177mg, 60 % as white solid, m.p.: 127-129 °C; HRMS (ESI) m/z calcd for C₁₇H₂₂N₅ [M+H]⁺ :



296.1870; found: 296.1869; ¹H NMR (500 MHz, CDCl₃) δ 7.16 – 7.12 (m, 1H), 7.07 (d, *J* = 7.5 Hz, 2H), 7.03 (d, *J* = 5.2 Hz, 1H), 6.04 (d, *J* = 5.2 Hz, 1H), 2.28 – 2.22 (m, 2H), 2.06 (s, 6H), 1.90 – 1.80 (m, 2H), 1.78 – 1.71 (m, 1H), 1.67 – 1.60 (m, 2H), 1.55 – 1.47 (m, 2H), 1.22 – 1.11 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 148.4, 139.6, 138.9, 128.6, 128.1, 126.2, 100.8, 59.7, 32.6, 25.1, 22.1, 18.8.

8g: N-(1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)cyclohexyl)pyridin-2-amine.

The product was obtained using procedure **A**, 358 mg, 54 % as white solid, m.p.: 126-128 °C; HRMS (ESI) m/z calcd for C₁₆H₂₅N₆O₂




[M+H]⁺ : 333.2033; found: 333.2032; ¹H NMR (500 MHz, CDCl₃) δ 7.98 (dd, *J* = 8.0, 0.8 Hz, 1H), 7.35 – 7.31 (m, 1H), 6.62 (dd, *J* = 7.2, 5.0 Hz, 1H), 6.06 (d, *J* = 8.0 Hz, 1H), 4.94 (s, 1H), 4.77 (t, *J* = 5.6 Hz, 1H), 4.52 (d, *J* = 5.6 Hz, 2H), 3.31 (s, 6H),

2.44 – 2.37 (m, 2H), 2.25 – 2.17 (m, 2H), 1.78 – 1.68 (m, 3H), 1.63 – 1.54 (m, 2H), 1.49 – 1.39 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 159.6, 155.9, 148.4, 137.5, 114.6, 108.2, 103.0, 55.5, 53.6, 49.9, 34.4, 24.9, 21.0.

2g: 7'-(pyridin-2-yl)-7'H-spiro[cyclohexane-1,8'-tetrazolo[1,5-a]pyrazine].

The product was obtained using procedure **B**, 80mg, 30 % as white solid, m.p.:




132-134 °C; HRMS (ESI) m/z calcd for C₁₄H₁₇N₆ [M+H]⁺ : 269.1509; found: 269.1509; ¹H NMR (500 MHz, CDCl₃) δ 8.47 (dd, *J* = 5.0, 1.7 Hz, 1H), 7.74 (td, *J* = 7.5, 1.9 Hz, 1H),

7.19 (dd, *J* = 7.5, 5.0 Hz, 1H), 7.03 (d, *J* = 7.5 Hz, 1H), 6.87 (d, *J* = 5.7 Hz, 1H), 6.41 (d, *J* = 5.7 Hz, 1H), 2.53 – 2.45 (m, 2H), 2.27 – 2.23 (m, 2H), 2.06 – 1.96 (m, 2H), 1.79 – 1.66 (m, 3H), 1.34 – 1.24 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 155.8, 150.0, 148.2, 138.2, 126.7, 121.1, 120.5, 99.5, 62.0, 32.0, 24.7, 22.4.

8h: 1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)-N-phenethylpropan-1-amine.


The product was obtained using procedure **A**, 402 mg, 63 % as liquid; HRMS



(ESI) m/z calcd for C₁₆H₂₅N₅O₂ [M+H]⁺ : 320.2081; found: 320.2081; ¹H NMR (500 MHz, CDCl₃) δ 7.29 (t, *J* = 7.5 Hz, 2H), 7.21 (t, *J* = 7.5 Hz, 1H), 7.14 (d, *J* = 7.5 Hz, 2H), 4.76 (t, *J* = 5.4 Hz, 1H), 4.48 (dd, *J* = 14.1, 5.4

Hz, 1H), 4.40 (dd, *J* = 14.1, 5.4 Hz, 1H), 4.10 (t, *J* = 7.0 Hz, 1H), 3.39 (s, 3H), 3.36 (s, 3H), 2.80 – 2.63 (m, 4H), 1.95 – 1.84 (m, *J* = 13.8, 7.0 Hz, 2H), 0.89 (t, *J* = 7.4, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 157.0, 139.5, 128.6, 128.4, 126.2, 102.7, 55.0, 54.3, 49.0, 48.3, 36.3, 27.2, 27.2, 10.3.

2h: 8-ethyl-7-phenethyl-7,8-dihydro-tetrazolo[1,5-a]pyrazine.




The product was obtained using procedure **B**, 117 mg, 46 % as brown solid, m.p.: 89-91 °C; HRMS (ESI) m/z calcd for C₁₄H₁₇N₅ [M+H]⁺ : 256.1562; found:

256.1563; ^1H NMR (500 MHz, CDCl_3) δ 7.29 – 7.20 (m, 3H), 7.11 – 7.08 (m, 2H), 6.44 (d, $J = 5.6$ Hz, 1H), 6.00 (d, $J = 5.6$ Hz, 1H), 4.91 (t, $J = 5.6$ Hz, 1H), 3.51 – 3.40 (m, 2H), 2.92 – 2.82 (m, 2H), 1.90 – 1.82 (m, 2H), 0.88 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 145.4, 137.7, 128.7, 128.6, 128.1, 126.8, 94.9, 55.9, 54.39, 35.6, 25.8, 8.6.

8i: N-(1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)propyl)butan-1-amine.

The product was obtained using procedure **A**, 222 mg, 41 % as white solid,



m.p.: 86-88 °C; HRMS (ESI) m/z calcd for $\text{C}_{12}\text{H}_{26}\text{N}_5\text{O}_2$

$[\text{M}+\text{H}]^+$: 272.2081; found: 272.2079; ^1H NMR (500 MHz,

CDCl_3) δ 4.80 (t, $J = 5.5$ Hz, 1H), 4.60 – 4.50 (m, 2H), 4.06

(t, $J = 7.0$ Hz, 1H), 3.42 (s, 3H), 3.40 (s, 3H), 2.48 – 2.41

(m, 1H), 2.40 – 2.33 (m, 1H), 1.94 – 1.87 (m, 2H), 1.45 – 1.35 (m, 2H), 1.35 –


1.23 (m, 2H), 0.92 (t, $J = 7.4$ Hz, 3H), 0.87 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (126

MHz, CDCl_3) δ 157.4, 102.8, 55.6, 55.4, 54.7, 49.0, 47.0, 32.2, 27.4, 20.3, 13.8,

10.3.

2i: 7-butyl-8-ethyl-7,8-dihydro-tetrazolo[1,5-a]pyrazine.

The product was obtained using procedure **B**, 113 mg, 55 % as yellow liquid;



HRMS (ESI) m/z calcd for $\text{C}_{10}\text{H}_{18}\text{N}_5$ $[\text{M}+\text{H}]^+$: 208.1562;

found: 208.1563; ^1H NMR (500 MHz, CDCl_3) δ 6.48 (d, J

= 5.6 Hz, 1H), 6.10 (d, $J = 5.6$ Hz, 1H), 5.04 (t, $J = 5.4$ Hz,


1H), 3.27 – 3.12 (m, 2H), 1.94 – 1.87 (m, 2H), 1.64 – 1.54 (m, 2H), 1.41 – 1.29

(m, 2H), 0.96 (t, $J = 7.3$ Hz, 3H), 0.91 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (126 MHz,

CDCl_3) δ 145.5, 128.5, 94.4, 55.6, 52.3, 30.8, 25.4, 19.7, 13.7, 8.6.

11a: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methyl)propan-2-amine.

The product was obtained using procedure **A**, 726 mg, 92 % as white solid,




m.p.: 93-95 °C; HRMS (ESI) m/z calcd for $C_{18}H_{30}N_5O_5$ $[M+H]^+$: 396.2242; found: 396.2242; 1H NMR (500 MHz, $CDCl_3$) δ 6.54 (s, 2H), 5.30 (s, 1H), 4.57 (t, $J = 5.0$ Hz, 1H), 4.42 (dd, $J = 14.2, 5.0$ Hz, 1H), 4.23 (dd, $J = 14.2, 5.0$ Hz, 1H), 3.83 (s, 6H), 3.81 (s, 3H), 3.38 (s, 3H), 3.37 (s, 3H), 2.83 – 2.72 (m, 1H), 2.17 (s, 1H), 1.12 (t, $J = 6.0$, 6H); ^{13}C

NMR (126 MHz, $CDCl_3$) δ 156.9, 153.6, 137.8, 133.8, 104.3, 102.8, 60.7, 56.1, 55.8, 55.4, 54.6, 49.0, 46.1, 22.6, 22.5.

3a: N-isopropyl-7,8,9-trimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine


The product was obtained using procedure **B**, 188 mg, 57 % as white solid, m.p.:



93-95 °C; HRMS (ESI) m/z calcd for $C_{16}H_{22}N_5O_3$ $[M+H]^+$: 332.1717; found: 332.1716; 1H NMR (500 MHz, $CDCl_3$) δ 7.54 (d, $J = 9.5$ Hz, 1H), 7.20 (d, $J = 9.5$ Hz, 1H), 6.90 (s, 1H), 5.33 (s, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 3.86 (s, 3H),

2.53 (dt, $J = 11.9, 6.0$ Hz, 1H), 1.65 (s, 1H), 1.10 (d, $J = 6.0$ Hz, 3H), 0.96 (d, $J = 6.0$ Hz, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 155.7, 153.9, 152.3, 141.8, 133.2, 118.0, 117.1, 107.9, 103.6, 61.5, 60.9, 56.1, 54.2, 46.3, 23.1, 22.2.

11b: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methyl)-N-propylpropan-1-amine.




The product was obtained using procedure **A**, 725 mg, 83 % as white solid, m.p.: 63-65 °C; HRMS (ESI) m/z calcd for $C_{21}H_{36}N_5O_5$ $[M+H]^+$: 438.2711; found: 438.2710; 1H NMR (500 MHz, $CDCl_3$) δ 6.55 (s, 2H), 5.40 (s, 1H), 4.64 (t, $J = 5.5$ Hz, 1H), 4.50 (dd, $J = 14.2, 5.5$ Hz, 1H),

4.36 (dd, $J = 14.2, 5.5$ Hz, 1H), 3.84 (s, 3H), 3.82 (s, 6H), 3.40 (s, 3H), 3.31 (s, 3H), 2.54 – 2.49 (m, 4H), 1.50-1.38 (m, 4H), 0.81 (t, $J = 7.3$ Hz, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.4, 153.0, 137.8, 131.7, 106.5, 102.8, 60.8, 59.5, 56.2, 55.8, 55.5, 52.6, 49.2, 21.0, 11.7.

3b: 7,8,9-trimethoxy-N,N-dipropyl-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.

The product was obtained using procedure **B**, 283 mg, 76 % as oil; HRMS (ESI)




m/z calcd for $\text{C}_{19}\text{H}_{28}\text{N}_5\text{O}_3$ $[\text{M}+\text{H}]^+$: 374.2187; found: 374.2185; ^1H NMR (500 MHz, CDCl_3) δ 7.51 (d, $J = 9.4$ Hz, 1H), 7.17 (d, $J = 9.4$ Hz, 1H), 6.79 (s, 1H), 5.34 (s, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 3.90 (s, 3H), 2.21 – 2.11 (m, 4H), 1.32 – 1.05 (m, 4H), 0.63 (t, $J = 7.4$ Hz, 6H);

^{13}C NMR (126 MHz, CDCl_3) δ 154.8, 153.5, 152.0, 142.0, 132.2, 119.1, 117.8, 117.2, 109.8, 61.9, 61.3, 60.8, 56.0, 51.8, 18.8, 11.3.

11c: N-(4-chlorobenzyl)-1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)-1-(3,4,5-trimethoxyphenyl)methanamine.

The product was obtained using procedure **A**, 300 mg, 63 % as oil; HRMS (ESI)




m/z calcd for $\text{C}_{22}\text{H}_{29}\text{ClN}_5\text{O}_5$ $[\text{M}+\text{H}]^+$: 478.1852, found: 478.1852; ^1H NMR (500 MHz, CDCl_3) δ 7.33 – 7.26 (m, 4H), 6.53 (s, 2H), 5.17 (s, 1H), 4.51 (t, $J = 5.4$ Hz, 1H), 4.33 (dd, $J = 14.2, 4.9$ Hz, 1H), 4.18 (dd, $J = 14.2, 5.9$ Hz, 1H), 3.83 (s, 3H), 3.82 (s, 6H), 3.76 (s, 2H), 3.30 (s, 6H), 2.55 (s, 1H); ^{13}C NMR (126 MHz, CDCl_3) δ 156.3, 153.7, 137.5, 133.1, 129.6, 128.6, 104.7, 102.6, 60.8, 56.2, 56.2,

55.5, 55.4, 50.5, 49.0.

3c: N-(4-chlorobenzyl)-7,8,9-trimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.


The product was obtained using procedure **B**, 223 mg, 54 % as white solid, m.p.:



156-158 °C; HRMS (ESI) m/z calcd for $C_{20}H_{20}ClN_5O_3$ $[M+H]^+$: 414.1327; found: 414.1329; 1H NMR (500 MHz, $CDCl_3$) δ 7.52 (d, $J = 9.5$ Hz, 1H), 7.28 – 7.25 (m, 2H), 7.21 – 7.16 (m, 3H), 6.79 (s, 1H), 5.23 (s, 1H), 3.92 (s, 3H), 3.90 (s, 3H), 3.88 (d, $J = 4.5$ Hz, 3H), 3.63 (s, 2H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 155.6, 153.4, 152.4, 142.0, 137.2, 133.1, 132.4, 129.4, 128.6, 118.0, 117.1, 108.0, 61.5, 60.9, 56.1, 55.8, 50.4.


11d: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methyl) prop-2-en-1-amine.

The product was obtained using procedure **A**, 747 mg, 95 % as oil; HRMS (ESI)



m/z calcd for $C_{18}H_{28}N_5O_5$ $[M+H]^+$: 394.2085; found: 394.2083; 1H NMR (500 MHz, $CDCl_3$) δ 6.58 (s, 2H), 5.91 (dd, $J = 17.0, 10.4$ Hz, 1H), 5.24 (s, 1H), 5.23 - 5.14 (m, 2H), 4.55 (t, $J = 5.4$ Hz, 1H), 4.41 (dd, $J = 14.2, 5.4$ Hz, 1H), 4.27 (dd, $J = 14.2, 6.0$ Hz, 1H), 3.83 (s, 6H), 3.82 (s, 3H), 3.36 (s, 3H), 3.34 (s, 3H), 3.25 (dd, $J = 6.0, 1.1$ Hz, 2H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 156.4, 153.6, 138.0, 135.6, 133.3, 1176.0, 104.6, 102.6, 60.7, 56.3, 56.1, 55.5, 55.3, 49.9, 49.0.

3d: N-allyl-7,8,9-trimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.




The product was obtained using procedure **B**, 204 mg, 62 % as oil; HRMS (ESI) m/z calcd for $C_{16}H_{20}N_5O_3$ $[M+H]^+$: 330.1561; found: 330.1560; 1H NMR (500 MHz, $CDCl_3$) δ 7.55 (d, $J = 9.5$ Hz, 1H), 7.20 (d, $J = 9.5$ Hz, 1H), 6.92 (s, 1H), 5.83 – 5.72 (m, 1H), 5.29 (s, 1H), 5.14 (ddd, $J = 14.0, 11.2, 1.2$ Hz, 2H),

3.95 (s, 3H), 3.93 (s, 3H), 3.88 (s, 3H), 3.23 – 3.05 (m, 2H), 1.71 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 155.5, 153.5, 152.2, 141.8, 135.1, 132.5, 117.9, 117.8, 117.1, 117.0, 107.9, 61.4, 60.8, 56.0, 55.6, 49.6.

11e: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,5-dimethoxyphenyl)methyl) prop-2-en-1-amine.

The product was obtained using procedure A, 508 mg, 70 % as oil; HRMS (ESI)




m/z calcd for C₁₇H₂₆N₅O₄ [M+H]⁺ : 364.1979 found: 364.19779; ¹H NMR (500 MHz, CDCl₃) δ 6.49 (d, *J* = 2.2 Hz, 2H), 6.39 (t, *J* = 2.2 Hz, 1H), 5.90 (dd, *J* = 17.1, 10.2 Hz, 1H), 5.25 (s, 1H), 5.20 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.15 (dd, *J* = 10.2, 1.4 Hz, 1H), 4.56 (t, *J* = 5.5 Hz, 1H), 4.40

(dd, *J* = 14.2, 5.0 Hz, 1H), 4.25 (dd, *J* = 14.2, 5.9 Hz, 1H), 3.76 (s, 6H), 3.36 (s, 3H), 3.34 (s, 3H), 3.25 (d, *J* = 6.0 Hz, 2H), 2.25 (brs, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 161.2, 156.3, 140.0, 135.7, 116.9, 105.5, 102.4, 100.2, 56.2, 55.4, 55.3, 55.1, 49.9, 49.0.

3e: N-allyl-7,9-dimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.

The product was obtained using procedure B, 248 mg, 83 % as white solid, m.p.:




114-116 °C; HRMS (ESI) m/z calcd for C₁₅H₁₈N₅O₂ [M+H]⁺ : 300.1455; found: 300.1455; ¹H NMR (500 MHz, CDCl₃) δ 7.48 (d, *J* = 9.5 Hz, 1H), 7.23 (d, *J* = 9.5 Hz, 1H), 6.68 (d, *J* = 2.2 Hz, 1H), 6.49 (d, *J* = 2.2 Hz, 1H), 5.82 –

5.73 (m, 1H), 5.26 (s, 1H), 5.14 (ddd, *J* = 13.7, 11.4, 1.3 Hz, 2H), 3.88 (s, 3H), 3.87 (s, 3H), 3.19 – 3.06 (m, 2H), 1.74 (brs, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 162.8, 159.0, 153.5, 139.2, 135.2, 117.2, 117.1, 117.0, 113.0, 105.3, 98.3, 56.0, 55.9, 55.6, 49.8.

11f: 2-(3-chlorophenyl)-N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,5-dimethoxyphenyl)methyl)ethanamine.

The product was obtained using procedure A, 857 mg, 93 % as oil; HRMS (ESI)


m/z calcd for $C_{22}H_{29}N_5O_4$ $[M+H]^+$: 462.1903; found: 462.1902; 1H NMR (500 MHz, $CDCl_3$) δ 7.24 – 7.17 (m, 3H), 7.11 – 7.04 (m, 1H), 6.45 (d, $J = 2.2$ Hz, 2H), 6.40 (t, $J = 2.2$ Hz, 1H), 5.24 (s, 1H), 4.55 (t, $J = 5.5$ Hz, 1H), 4.40 (dd, $J = 14.2, 5.0$ Hz, 1H), 4.22 (dd, $J = 14.2, 5.9$ Hz, 1H), 3.75 (s, 6H), 3.34 (s, 6H), 2.90 – 2.79 (m, 4H), 2.15 (s, 1H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 161.2, 156.3, 141.6, 140.0, 134.1, 129.7, 128.7, 126.9, 126.4, 105.4, 102.5, 100.3, 57.3, 55.5, 55.3, 49.0, 48.5, 35.9.



3f: N-(3-chlorophenethyl)-7,9-dimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.


The product was obtained using procedure B, 333 mg, 84 % as oil; HRMS (ESI)

m/z calcd for $C_{20}H_{21}ClN_5O_2$ $[M+H]^+$: 398.1378; found: 398.1376; 1H NMR (500 MHz, $CDCl_3$) δ 7.31 (d, $J = 9.5$ Hz, 1H), 7.17 (d, $J = 5.0$ Hz, 2H), 7.10 (d, $J = 9.5$ Hz, 1H), 7.06 (s, 1H), 6.97 – 6.92 (m, 1H), 6.63 (d, $J = 2.3$ Hz, 1H), 6.47 (d, $J = 2.3$ Hz, 1H), 5.22 (s, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 2.87 – 2.77 (m, 1H), 2.75 – 2.64 (m, 3H), 1.69 (s, 1H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 162.8, 159.0, 153.4, 141.3, 139.1, 134.1, 129.7, 128.7, 126.8, 126.5, 116.9, 116.8, 112.8, 105.2, 98.4, 56.8, 55.9, 55.5, 48.0, 35.4.



11g: 4-benzyl-1-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,5-dimethoxyphenyl)methyl)piperidine.


The product was obtained using procedure A, 839 mg, 87 % as oil; HRMS (ESI)



m/z calcd for $C_{26}H_{36}N_5O_4$ $[M+H]^+$: 482.2762; found: 482.2760; 1H NMR (500 MHz, $CDCl_3$) δ 7.26 (d, $J = 7.8$ Hz, 2H), 7.17 (t, $J = 7.2$ Hz, 1H), 7.10 (d, $J = 7.8$ Hz, 2H), 6.55 (d, $J = 2.2$ Hz, 2H), 6.38 (t, $J = 2.2$ Hz, 1H), 4.96 (s, 1H), 4.65 (t, $J = 5.5$ Hz, 1H), 4.56 (dd, $J = 14.0, 5.5$ Hz, 1H), 4.37 (dd, $J = 14.0, 5.5$ Hz, 1H), 3.75 (s, 6H), 3.37 (s, 3H), 3.33 (s, 3H), 2.94-2.84 (m, 1H), 2.72 (dd, $J = 7.2, 3.8$ Hz, 1H), 2.52 (d, $J = 7.2$ Hz, 2H), 2.19-2.11 (m, 1H), 1.96-1.88 (m, 1H), 1.65-1.56 (m, 1H), 1.56 – 1.45 (m, 1H), 1.42-1.25 (m, 2H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 160.8, 155.3, 140.4, 137.4, 129.0, 128.1, 125.8, 107.0, 102.6, 100.1, 64.9, 55.4, 55.4, 55.3, 51.9, 51.0, 49.2, 43.0, 37.7, 32.2, 32.1.

3g: 11-(4-benzylpiperidin-1-yl)-7,9-dimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepine.


The product was obtained using procedure B, 400 mg, 96 % as white solid, m.p.



: 182-184 °C; HRMS (ESI) m/z calcd for $C_{24}H_{27}N_5O_2$ $[M+H]^+$: 418.2238; found: 418.2237; 1H NMR (500 MHz, $CDCl_3$) δ 7.41 (d, $J = 9.4$ Hz, 1H), 7.22 (t, $J = 7.4$ Hz, 2H), 7.17 (d, $J = 9.4$ Hz, 1H), 7.14 (t, $J = 7.4$ Hz, 1H), 7.05 (d, $J = 7.1$ Hz, 2H), 6.49 (dd, $J = 7.5, 2.3$ Hz, 2H), 4.89 (s, 1H), 3.86 (s, 3H), 3.82 (s, 3H), 2.47 – 2.33 (m, 3H), 2.23 – 2.17 (m, 1H), 1.92 (td, $J = 11.6, 2.0$, 1H), 1.75 (td, $J = 11.6, 2.0$ Hz, 1H), 1.50 – 1.41 (m, 2H), 1.06 – 0.96 (m, 2H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 162.1, 158.9, 152.9, 140.4, 138.0, 128.9, 128.1, 125.7, 117.1, 117.0, 113.9, 107.4, 98.4, 65.2, 55.9, 55.5, 51.9, 51.0, 42.8, 37.8, 31.7, 31.6.

11h: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,5-dimethoxyphenyl)methyl)aniline.

The product was obtained using procedure A, 790 mg, 99 % as oil; HRMS (ESI)




m/z calcd for $C_{20}H_{26}N_5O_4$ $[M+H]^+$: 400.1979; found: 400.1979; 1H NMR (500 MHz, $CDCl_3$) δ 7.15 (t, $J = 8.0$ Hz, 2H), 6.75 (t, $J = 7.4$ Hz, 1H), 6.66 (d, $J = 8.0$ Hz, 2H), 6.52 (d, $J = 2.2$ Hz, 2H), 6.39 (t, $J = 2.2$ Hz, 1H), 6.04 (d, $J = 7.1$ Hz, 1H), 5.02 (d, $J = 7.1$ Hz, 1H), 4.65 (dd, $J = 5.8, 4.8$ Hz, 1H), 4.41 (dd, $J = 14.3, 4.8$ Hz, 1H),

4.27 (dd, $J = 14.3, 6.0$ Hz, 1H), 3.73 (s, 6H), 3.41 (s, 3H), 3.39 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 161.4, 156.1, 145.8, 139.6, 129.3, 118.9, 113.7, 105.3, 102.9, 100.3, 55.8, 55.6, 55.4, 53.2, 49.3.

3h: 7,9-dimethoxy-N-phenyl-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.


The product was obtained using procedure B, 56 mg, 15 % as white solid, m.p. :



185-187 °C; HRMS (ESI) m/z calcd for $C_{18}H_{18}N_5O_2$ $[M+H]^+$: 336.1455; found: 336.1455; 1H NMR (500 MHz, $CDCl_3$) δ 7.49 (d, $J = 9.3$ Hz, 1H), 7.31 (d, $J = 9.3$ Hz, 1H), 7.16 (t, $J = 7.9$ Hz, 2H), 6.81-6.75 (m, 2H), 6.68 (d, $J = 8.0$ Hz, 2H), 6.49 (d, $J = 2.2$ Hz, 1H), 5.61 (s, 1H),

4.90 (s, 1H), 3.89 (s, 3H), 3.77 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 163.3, 158.9, 153.5, 145.8, 138.5, 129.4, 119.1, 118.3, 117.5, 113.6, 112.4, 103.5, 98.5, 56.0, 55.6, 53.0.

11i: 2-(3-chlorophenyl)-N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,4-dimethoxyphenyl)methyl)ethanamine.




The product was obtained using procedure A, 875 mg, 95 % as oil; HRMS (ESI) m/z calcd for $C_{22}H_{29}ClN_5O_4$ $[M+H]^+$: 462.1903; found: 462.1902; 1H NMR (500 MHz, $CDCl_3$) δ 7.25 – 7.15 (m, 3H), 7.07

(dd, $J = 7.0, 1.5$ Hz, 1H), 6.83 (s, 3H), 5.24 (s, 1H), 4.56 (t, $J = 6.0$ Hz, 1H), 4.38 (dd, $J = 14.2, 5.0$, 1H), 4.19 (dd, $J = 14.2, 6.0$, 1H), 3.87 (s, 3H), 3.82 (s, 3H), 3.34 (s, 6H), 2.91 – 2.76 (m, 4H); ^{13}C NMR (126 MHz, CDCl_3) δ 156.6, 149.6, 149.2, 141.6, 134.1, 130.1, 129.7, 128.7, 126.9, 126.4, 119.8, 111.1, 110.2, 102.7, 57.0, 55.9, 55.6, 55.4, 49.0, 48.5, 35.9.

3i: N-(3-chlorophenethyl)-8,9-dimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.

The product was obtained using procedure **B**, 107 mg, 27 % as oil; HRMS (ESI)




m/z calcd for $\text{C}_{20}\text{H}_{21}\text{ClN}_5\text{O}_2$ $[\text{M}+\text{H}]^+$: 398.1378; found: 398.1378; ^1H NMR (500 MHz, CDCl_3) δ 7.38 (d, $J = 9.4$ Hz, 1H), 7.18 – 7.16 (m, 2H), 7.05 (s, 1H), 6.98 (s, 1H), 6.93 (td, $J = 4.6, 1.6$ Hz, 1H), 6.84 (d, $J = 3.4$ Hz, 1H), 6.65 (d, $J = 9.4$ Hz, 1H), 5.32 (s, 1H), 3.93 (s, 3H), 3.90

(s, 3H), 2.85-2.77 (m, 1H), 2.73-2.62 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 153.3, 151.0, 148.8, 141.2, 134.1, 129.7, 129.2, 128.7, 126.8, 126.4, 123.5, 122.0, 117.8, 113.4, 112.2, 56.3, 56.1, 47.7, 35.3.

11j: 4-benzyl-1-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,4-dimethoxyphenyl)methyl)piperidine.

The product was obtained using procedure **A**, 701 mg, 73 % as oil; HRMS (ESI)




m/z calcd for $\text{C}_{26}\text{H}_{36}\text{N}_5\text{O}_4$ $[\text{M}+\text{H}]^+$: 482.2762; found: 482.2761; ^1H NMR (500 MHz, CDCl_3) δ 7.24 (t, $J = 7.4$ Hz, 2H), 7.16 (t, $J = 7.4$ Hz, 1H), 7.10 (d, $J = 7.0$ Hz, 2H), 6.99 (d, $J = 1.9$ Hz, 1H), 6.89 (dd, $J = 8.2, 1.9$ Hz, 1H), 6.80 (d, $J = 8.2$ Hz, 1H), 4.97 (s, 1H), 4.66 (t, $J = 5.5$ Hz, 1H), 4.56 (dd, $J =$

14.1, 5.5 Hz, 1H), 4.37 (dd, $J = 14.1, 5.5$ Hz, 1H), 3.86 (s, 3H), 3.85 (s, 3H) 3.38 (s, 3H), 3.32 (s, 3H), 2.85 (d, $J = 11.2$ Hz, 1H), 2.75 (d, $J = 11.2$ Hz, 1H), 2.51 (d, $J = 7.1$ Hz, 2H), 2.16 – 2.10 (m, 1H), 1.91 (td, $J = 11.2, 2.1$ Hz, 1H), 1.61

(dd, $J = 17.1, 7.1$ Hz, 1H), 1.49 (dd, $J = 7.4, 3.7$ Hz, 1H), 1.41 – 1.26 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.6, 149.0, 140.4, 129.0, 128.1, 127.3, 125.7, 121.5, 112.0, 110.6, 102.7, 64.4, 55.9, 55.8, 55.5, 55.4, 51.7, 50.6, 49.1, 43.0, 37.7, 32.2, 32.1.

3j: 11-(4-benzylpiperidin-1-yl)-8,9-dimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepine.

The product was obtained using procedure **B**, 171 mg, 41 % as white solid, m.p.:




201-202 °C; HRMS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{28}\text{N}_5\text{O}_2$ $[\text{M}+\text{H}]^+$: 418.2238; found: 418.2236; ^1H NMR (500 MHz, CDCl_3) δ 7.48 (d, $J = 9.2$ Hz, 1H), 7.21 (t, $J = 7.5$ Hz, 2H), 7.13 (t, $J = 7.5$ Hz, 1H), 7.04 (d, $J = 7.5$ Hz, 2H), 6.87 (s, 1H), 6.85 (s, 1H), 6.72 (d, $J = 9.2$ Hz, 1H), 4.95 (s, 1H),

3.91 (s, 3H), 3.90 (s, 3H), 2.41 (dd, $J = 6.5, 3.4$ Hz, 2H), 2.33 (d, $J = 11.2$ Hz, 1H), 2.24 (d, $J = 11.2$ Hz, 1H), 1.93 – 1.87 (m, 1H), 1.74 (dd, $J = 17.1, 5.9$ Hz, 1H), 1.50 – 1.38 (m, 2H), 1.06-0.94 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3) δ 152.7, 150.4, 148.7, 140.2, 128.8, 127.9, 125.6, 124.4, 122.3, 117.8, 113.9, 113.2, 64.2, 56.0, 55.9, 51.5, 50.7, 42.7, 37.6, 31.6.

14a: 1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)-N-(3,4-dimethoxyphenethyl)-2-methylpropan-1-amine

The product was obtained using procedure **A**, 730 mg, 93 % as liquid; HRMS




(ESI) m/z calcd for $\text{C}_{19}\text{H}_{32}\text{N}_5\text{O}_4$ $[\text{M}+\text{H}]^+$: 394.2449; found: 394.2448; ^1H NMR (500 MHz, CDCl_3) δ 6.77 (d, $J = 8.0$ Hz, 1H), 6.70 – 6.64(m, 2H), 4.78 (t, $J = 5.5$ Hz, 1H), 4.42 (d, $J = 5.5$ Hz, 2H), 3.85 (s, 6H), 3.41 (s, 3H), 3.32 (s, 3H), 2.71 – 2.60 (m, 4H), 2.18 - 2.07 (m,

1H), 1.59 (brs, 1H), 0.99 (d, $J = 6.7$ Hz, 3H), 0.81 (d, $J = 6.7$ Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 156.8, 148.8, 147.3, 132.1, 120.4, 111.7, 111.1, 102.8, 59.2, 55.8, 55.7, 55.5, 49.0, 48.6, 35.7, 32.1, 19.3, 19.0.

4a: 8-isopropyl-2,3-dimethoxy-6,8,13,13a-tetrahydro-5H-tetrazolo [1',5':4,5]pyrazino[2,1-a]isoquinoline

The product was obtained using procedure C, 187 mg, 57 % as pale pink solid,




m.p.: 188-190 °C; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{24}\text{N}_5\text{O}_2$ $[\text{M}+\text{H}]^+$: 330.1925; found: 330.1924; ^1H NMR (500 MHz, CDCl_3) δ 6.68 (s, 1H), 6.61 (s, 1H), 4.61 (dd, $J = 13.1, 4.0$ Hz, 1H), 4.44 (dd, $J = 10.8, 4.0$ Hz, 1H), 4.35 – 4.26 (m, 1H), 3.88 (s, 6H), 3.81 (d, $J =$

8.0 Hz, 1H), 3.23 – 3.12 (m, 1H), 3.06 (td, $J = 11.3, 3.1$ Hz, 1H), 2.87 (dd, $J = 10.9, 6.2$ Hz, 1H), 2.72 (d, $J = 15.3$ Hz, 1H), 2.25 – 2.12 (m, 1H), 1.17 (d, $J = 6.6$ Hz, 3H), 1.08 (d, $J = 6.6$ Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 151.9, 148.6, 147.5, 126.3, 124.8, 111.9, 109.3, 64.8, 56.3, 56.1, 55.8, 51.4, 46.6, 46.2, 32.2, 29.1, 19.7

14b: N-((4-chlorophenyl)(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)methyl)-2-(3,4-dimethoxyphenyl)ethanamine

The product was obtained using procedure A, 783 mg, 85 % as pale yellow




liquid; HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{29}\text{ClN}_5\text{O}_4$ $[\text{M}+\text{H}]^+$: 462.1903; found: 462.1902; ^1H NMR (500 MHz, CDCl_3) δ 7.31 (d, $J = 8.4$ Hz, 2H), 7.25 (d, $J = 8.4$ Hz, 2H), 6.78 (d, $J = 8.1$ Hz, 1H), 6.70 (m, 2H), 5.26 (s, 1H), 4.56 (t, $J = 5.4$ Hz, 1H), 4.38 (dd, $J = 14.2, 5.5$ Hz, 1H), 4.23 (dd, $J = 14.2, 5.5$ Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 3.33 (s, 3H), 3.29 (s, 3H), 2.85 –

2.72 (m, 4H), 2.05 (brs, 1H); ^{13}C NMR (126 MHz, CDCl_3) δ 156.2, 148.9, 147.6, 136.4, 134.3, 131.8, 129.1, 128.9, 120.5, 111.8, 111.3, 102.7, 56.5, 55.9, 55.8, 55.6, 55.5, 49.1, 48.8, 35.7.

4b:8-(4-chlorophenyl)-2,3-dimethoxy-6,8,13,13a-tetrahydro-5H-tetrazolo[1',5':4,5]pyrazino[2,1-a]isoquinoline

The product was obtained using procedure C, 353 mg, 89 % as white solid,




m.p.: 119-121 °C; HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{21}\text{ClN}_5\text{O}_2$ $[\text{M}+\text{H}]^+$: 398.1378; found: 398.1379; ^1H NMR (500 MHz, CDCl_3) δ 7.31 (d, $J = 8.4$ Hz, 2H), 7.27 (d, $J = 8.4$ Hz, 2H), 6.68 (s, 1H), 6.53 (s, 1H), 5.53 (s, 1H), 4.72 (dd, $J = 11.6, 3.2$ Hz, 1H), 4.39 – 4.27 (m, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 3.17 – 3.05 (m, 2H),

2.97 – 2.87 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3) δ 151.1, 148.7, 147.7, 134.4, 134.0, 129.2, 128.8, 126.2, 124.3, 111.9, 109.0, 108.7, 60.4, 56.1, 55.9, 50.1, 48.2, 46.0, 29.1.

14c: 1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)-N-(3,4-dimethoxyphenethyl)cyclohexanamine

The product was obtained using procedure A, 569 mg, 68 % as white solid,




m.p.: 94-96 °C; HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{34}\text{N}_5\text{O}_4$ $[\text{M}+\text{H}]^+$: 420.2605; found: 420.2604; ^1H NMR (500 MHz, CDCl_3) δ 6.81 (d, $J = 8.1$ Hz, 1H), 6.69 (dd, $J = 8.1, 1.6$ Hz, 1H), 6.65 (d, $J = 1.6$ Hz, 1H), 4.96 (t, $J = 5.7$ Hz, 1H), 4.66 (d, $J = 5.7$ Hz, 2H),

3.88 (s, 3H), 3.87 (s, 3H), 3.41 (s, 6H), 2.65 (t, $J = 6.5$ Hz, 2H), 2.45 (t, $J = 6.5$ Hz, 2H), 2.14 – 2.04 (m, 2H), 1.99 – 1.90 (m, 2H), 1.68 – 1.56 (m, 2H), 1.51 (s, 1H), 1.40 – 1.31 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 158.9, 148.9, 147.5, 132.2, 120.7, 111.5, 111.3, 103.1, 55.8, 55.7, 55.6, 55.5, 55.5, 55.3, 49.9, 43.1, 35.9, 34.6, 24.9, 21.3.

4c: 2',3'-dimethoxy-5',6',13',13a'-tetrahydrospiro[cyclohexane-1,8'-tetrazolo[1',5':4,5]pyrazino[2,1-a]isoquinoline]

The product was obtained using procedure C, 273 mg, 77 % as white solid,




m.p.: 228-230 °C; HRMS (ESI) m/z calcd for $C_{19}H_{26}N_5O_2$ $[M+H]^+$: 356.2081; found: 356.2081; 1H NMR (500 MHz, $CDCl_3$) δ 6.69 (s, 1H), 6.61 (s, 1H), 4.66 (dd, $J = 11.1, 4.9$ Hz, 1H), 4.56 (dd, $J = 13.1, 4.9$ Hz, 1H), 4.32 (dd, $J = 13.1, 11.1$ Hz, 1H), 3.88 (s, 6H),

3.20 – 3.12 (m, 1H), 3.09 – 3.00 (m, 1H), 2.81 – 2.75 (m, 1H), 2.73 – 2.64 (m, 1H), 2.38 – 2.28 (m, 1H), 2.20-2.06 (m, 2H), 2.00 – 1.91 (m, 1H), 1.84 – 1.73 (m, 2H), 1.69 – 1.50 (m, 4H); ^{13}C NMR (126 MHz,) δ 156.6, 148.6, 147.5, 126.6, 125.7, 111.7, 109.3, 57.1, 56.1, 56.0, 55.8, 50.3, 46.7, 37.5, 35.3, 32.3, 29.4, 25.3, 20.8.

14d: N-(2-(1H-indol-3-yl)ethyl)-1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)cyclohexanamine

The product was obtained using procedure A, 748 mg, 94 % as white solid,




m.p.: 101-103 °C; HRMS (ESI) m/z calcd for $C_{21}H_{31}N_6O_2$ $[M+H]^+$: 399.2503; found: 399.2503; 1H NMR (500 MHz, $CDCl_3$) δ 8.02 (s, 1H), 7.52 (d, $J = 8.0$ Hz, 1H), 7.36 (d, $J = 8.0$ Hz, 1H), 7.20 (t, $J = 7.5$ Hz, 1H), 7.10 (t, $J = 7.5$ Hz, 1H), 6.98 (s, 1H), 4.93 (t, $J = 5.7$ Hz, 1H), 4.66 (d, $J = 5.7$ Hz, 2H), 3.36 (s, 6H), 2.87 (t, $J = 6.5$ Hz, 2H), 2.53 (t, $J = 6.5$ Hz, 2H), 2.13

– 2.01 (m, 2H), 1.96-1.85 (m, 2H), 1.57 – 1.50 (m, 3H), 1.48-1.38 (m, 1H), 1.36 – 1.27 (m, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 159.1, 136.3, 127.2, 121.9, 121.8, 119.2, 118.5, 113.4, 111.2, 102.9, 55.4, 55.3, 49.9, 42.2, 34.7, 25.8, 25.0, 21.3.

4d: 7',12',12b',13'-tetrahydro-6'H-spiro[cyclohexane-1,4'-tetrazolo [1'',5'':4',5'] pyrazino[1',2':1,2]pyrido[3,4-b]indole]

The product was obtained using procedure C, 177 mg, 53 % as white solid,



m.p.: 235-237 °C; HRMS (ESI) m/z calcd for $C_{19}H_{23}N_6$

$[M+H]^+$: 335.1979; found: 335.1979; 1H NMR (500 MHz,

$CDCl_3$) δ 8.60 (brs, 1H), 7.54 (d, $J = 8.0$ Hz, 1H), 7.40 (d,

$J = 8.0$ Hz, 1H), 7.21 (t, $J = 7.3$ Hz, 1H), 7.15 (t, $J = 7.3$

Hz, 1H), 4.90 – 4.81 (m, 1H), 4.76 – 4.67 (m, 1H), 4.43-

4.32 (m, 1H), 3.29-3.19 (m, 1H), 3.02 – 2.77 (m, 3H), 2.30-2.18 (m, 2H), 2.14-


2.02 (m, 2H), 1.83 – 1.52 (m, 6H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 157.1, 136.5,

131.0, 126.6, 122.3, 119.9, 118.5, 111.3, 109.9, 57.7, 47.3, 46.8, 39.3, 34.5,

32.9, 25.3, 22.6, 21.1, 21.1.

14e: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(4-nitrophenyl)methyl)-2-(1H-indol-3-yl)ethanamine

The product was obtained using procedure A, 883 mg, 98 % as brown liquid;



HRMS (ESI) m/z calcd for $C_{22}H_{26}N_7O_4$ $[M+H]^+$:

452.2041; found: 452.2040; 1H NMR (500 MHz,

$CDCl_3$) δ 8.17 (brs, 1H), 8.09 (d, $J = 8.4$ Hz, 2H), 7.46

(d, $J = 8.0$ Hz, 1H), 7.43 (d, $J = 8.4$ Hz, 2H), 7.34 (d, $J =$

8.0 Hz, 1H), 7.18 (t, $J = 7.5$ Hz, 1H), 7.05 (t, $J = 7.5$ Hz,

1H), 7.01 (s, 1H), 5.34 (s, 1H), 4.57 (t, $J = 5.1$ Hz, 1H),

4.38 (dd, $J = 14.1, 5.0$ Hz, 1H), 4.30 (dd, $J = 14.1, 5.0$ Hz, 1H), 3.32 (s, 3H),


3.23 (s, 3H), 3.05-2.82 (m, 4H), 2.13 (brs, 1H); ^{13}C NMR (126 MHz, $CDCl_3$) δ

155.8, 147.7, 145.0, 136.4, 128.7, 128.6, 127.1, 123.9, 122.2, 119.3, 118.5,

112.9, 111.3, 102.4, 56.5, 56.3, 49.2, 47.4, 25.6.

4e: 4-(4-nitrophenyl)-4,6,7,12,12b,13-hexahydro-tetrazolo[1'',5'':4',5']pyrazino[1',2':1,2]pyrido[3,4-b]indole

The product was obtained using procedure C, 367 mg, 95 % as white solid,




m.p.: decomposes at 236 °C; HRMS (ESI) m/z calcd for $C_{20}H_{18}N_7O_2$ $[M+H]^+$: 388.1517; found: 388.1516; 1H NMR (500 MHz, DMSO) δ 11.12 (s, 1H), 8.28 (d, J = 8.7 Hz, 2H), 7.82 (d, J = 8.7 Hz, 2H), 7.42 (dd, J = 13.8, 8.0 Hz, 2H), 7.12 (t, J = 7.4 Hz, 1H), 7.01 (t, J = 7.4 Hz, 1H), 5.39 (dd, J = 12.1, 3.2 Hz, 1H), 5.36 (s, 1H), 4.57

(d, J = 10.4 Hz, 1H), 4.46 (t, J = 11.4 Hz, 1H), 2.98 – 2.90 (m, 1H), 2.74 – 2.62 (m, 3H); ^{13}C NMR (126 MHz, DMSO) δ 153.7, 148.7, 147.0, 137.3, 131.2, 131.1, 127.0, 125.0, 124.9, 122.4, 119.8, 119.0, 118.9, 112.3, 109.0, 62.8, 55.3, 49.6, 49.0, 22.1.

14f: N-(2-(1H-indol-3-yl)ethyl)-1-benzyl-4-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)piperidin-4-amine

The product was obtained using procedure A, 850 mg, 87 % as pale yellow




liquid; HRMS (ESI) m/z calcd for $C_{27}H_{36}N_7O_2$ $[M+H]^+$: 490.2925; found: 490.2925; 1H NMR (500 MHz, $CDCl_3$) δ 8.11 (s, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.31 – 7.17 (m, 6H), 7.10 (t, J = 7.4 Hz, 1H), 6.95 (s, 1H), 4.89 (t, J = 5.7 Hz, 1H), 4.60 (d, J = 5.6 Hz, 2H), 3.34 (s, 6H), 3.31 (s, 2H), 2.85 (t, J = 6.3 Hz, 2H),

2.52 (t, J = 6.1 Hz, 2H), 2.45 (s, 2H), 2.34 (d, J = 9.4 Hz, 2H), 2.17 (s, 2H), 1.90 (s, 2H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 158.2, 138.2, 136.3, 129.0, 128.1, 127.2, 127.0, 122.1, 121.9, 119.4, 118.6, 113.4, 111.2, 103.0, 62.8, 55.4, 53.8, 49.8, 49.0, 42.0, 34.7, 25.7.

4f: 1-benzyl-7',12',12b',13'-tetrahydro-6'H-spiro[piperidine-4,4'-tetrazolo [1'',5'':4',5']pyrazino[1',2':1,2]pyrido[3,4-b]indole]


The product was obtained using procedure C, 306 mg, 72 % as white solid,



m.p.: 156-158 °C; HRMS (ESI) m/z calcd for $C_{25}H_{28}N_7$ $[M+H]^+$: 426.2401; found: 426.2400; 1H NMR (500 MHz, $CDCl_3$) δ 8.29 (brs, 1H), 7.55 (d, $J = 8.0$ Hz, 1H), 7.40 (d, $J = 8.0$ Hz, 1H), 7.38 – 7.28 (m, 4H), 7.28 – 7.20(m, 2H), 7.16 (t, $J = 7.3$ Hz, 1H), 4.79 (dd, $J = 10.4$, 4.0 Hz, 1H), 4.72 (dd, $J = 12.8$, 4.0 Hz, 1H), 4.37 (t, $J = 11.8$ Hz, 1H), 3.60 (s, 2H), 3.24 – 3.11 (m, 2H), 3.08-2.92 (m, 2H), 2.87 – 2.79 (m, 1H), 2.74 – 2.60 (m, 3H), 2.40-2.34 (m, 2H), 2.24 – 2.13 (m, 1H), 2.01 – 1.91 (m, 1H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 156.6, 138.5, 136.5, 130.7, 129.0, 128.2, 127.0, 126.6, 122.3, 119.8, 118.5, 111.3, 109.8, 62.8, 56.4, 48.8, 48.5, 47.7, 47.0, 39.6, 33.7, 32.7, 22.5.

14g: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methyl)-2-(1H-indol-3-yl)ethanamine


The product was obtained using procedure A, 853 mg, 86 % as pale yellow



liquid; HRMS (ESI) m/z calcd for $C_{25}H_{33}N_6O_5$ $[M+H]^+$: 497.2507; found: 497.2506; 1H NMR (500 MHz, $CDCl_3$) δ 8.34 (s, 1H), 7.54 (d, $J = 8.0$ Hz, 1H), 7.34 (d, $J = 8.0$ Hz, 1H), 7.16 (t, $J = 7.5$ Hz, 1H), 7.07 (t, $J = 7.5$ Hz, 1H), 7.03 (s, 1H), 6.48 (s, 2H), 5.24 (s, 1H), 4.48 (t, $J = 5.0$ Hz, 1H), 4.37 (dd, $J = 14.1$, 5.0 Hz, 1H), 4.25 (dd, $J = 14.1$, 5.0 Hz, 1H), 3.80 (s, 3H), 3.71 (s, 6H), 3.29 (s, 3H), 3.28 (s, 3H), 3.07 – 2.91 (m, 4H), 2.17 (s, 1H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 156.5, 153.5, 137.7, 136.3, 133.4, 127.3, 122.2, 122.0, 119.2, 118.6, 113.2, 111.2, 104.3, 102.5, 60.7, 57.4, 56.0, 55.4, 55.2, 48.9, 47.7, 25.6.

**4g: 4-(3,4,5-trimethoxyphenyl)-4,6,7,12,12b,13-hexahydrotetrazolo
[1'',5'':4',5']pyrazino[1',2':1,2]pyrido[3,4-b]indole**

The product was obtained using procedure C, 138 mg, 32 % as white solid,



m.p.: 195-197 °C; HRMS (ESI) m/z calcd for

C₂₃H₂₅N₆O₃ [M+H]⁺ : 433.1983; found: 433.1982; ¹H

NMR (500 MHz, CDCl₃) δ 8.90 (s, 1H), 7.52 (d, *J* = 7.7

Hz, 1H), 7.34 (d, *J* = 8.1 Hz, 1H), 7.20 (t, *J* = 7.5 Hz,

1H), 7.14 (t, *J* = 7.4 Hz, 1H), 6.69 (s, 2H), 5.02 (dd, *J* =

12.1, 3.2 Hz, 1H), 4.70 (s, 1H), 4.29 (t, *J* = 11.5 Hz,

1H), 4.14 (d, *J* = 10.4 Hz, 1H), 3.85 (s, 3H), 3.80 (s, 6H), 3.21 (dd, *J* = 11.1, 4.3


Hz, 1H), 2.89 – 2.70 (m, 2H), 2.55 – 2.46 (m, 1H); ¹³C NMR (126 MHz, CDCl₃)

δ 153.8, 153.7, 137.9, 136.8, 133.0, 129.0, 126.4, 122.4, 119.8, 118.4, 111.3,

110.3, 105.2, 64.0, 60.8, 56.1, 55.1, 49.4, 48.1, 21.7.

**14h: methyl 2-((1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)cyclohexyl)
amino)-3-(1H-indol-3-yl)propanoate**

The product was obtained using procedure A, 802 mg, 88 % as white solid,



m.p.: 125-127 °C; HRMS (ESI) m/z calcd for

C₂₃H₃₃N₆O₄ [M+H]⁺ : 457.2558; found: 457.2558; ¹H

NMR (500 MHz, CDCl₃) δ 8.34 (brs, 1H), 7.45 (d, *J* =

7.5 Hz, 1H), 7.36 (d, *J* = 8.1 Hz, 1H), 7.18 (t, *J* = 7.5 Hz,

1H), 7.09 (t, *J* = 7.5 Hz, 1H), 6.87 (s, 1H), 4.76 (t, *J* = 5.6

Hz, 1H), 4.46 (dd, *J* = 14.4, 5.6 Hz, 1H), 4.09 – 3.98 (m, 1H), 3.49 (s, 3H), 3.42

– 3.35 (m, 1H), 3.32 (s, 3H), 3.29 (s, 3H), 2.99 (dd, *J* = 14.3, 5.0 Hz, 1H), 2.87

(dd, *J* = 14.3, 8.7 Hz, 1H), 2.31-2.15 (d, *J* = 13.2 Hz, 2H), 2.10 (brs, 1H), 1.78 –


1.53 (m, 3H), 1.50 – 1.11 (m, 5H); ¹³C NMR (126 MHz, CDCl₃) δ 176.0, 157.6,

136.0, 127.3, 122.6, 122.2, 119.6, 118.4, 111.2, 111.0, 102.9, 55.8, 55.7, 55.4,

55.2, 51.9, 50.1, 36.0, 35.5, 30.3, 25.1, 22.2, 21.9.

4h: methyl 7',12',12b',13'-tetrahydro-6'H-spiro[cyclohexane-1,4'-tetrazolo [1'',5'':4',5']pyrazino[1',2':1,2]pyrido[3,4-b]indole]-6'-carboxylate

The product was obtained using procedure C, 227 mg, 58 % as white solid,



m.p.: 235-237 °C; HRMS (ESI) m/z calcd for C₂₁H₂₅N₆O₂

[M+H]⁺ : 393.2034; found: 393.2033; ¹H NMR (500

MHz, CDCl₃) δ 8.51 (s, 1H), 7.50 (d, *J* = 8.0 Hz, 1H),

7.29 (d, *J* = 8.0 Hz, 1H), 7.17 (t, *J* = 7.5 Hz, 1H), 7.12 (t,

J = 7.5 Hz, 1H), 5.30 (d, *J* = 9.6 Hz, 1H), 5.00 (dd, *J* =

12.1, 3.1 Hz, 1H), 4.51 (d, *J* = 4.5 Hz, 1H), 3.91 (t, *J* = 11.4 Hz, 1H), 3.56 (s,

3H), 3.27 (d, *J* = 15.1 Hz, 1H), 3.16 (dd, *J* = 15.1, 4.5 Hz, 1H), 2.47 – 2.24 (m,

2H), 2.15-2.00 (m, 2H), 1.91 – 1.87 (m, 1H), 1.74 – 1.58 (m, 3H), 1.45 (td, *J* =

13.1, 4.1 Hz, 1H), 1.28 – 1.15 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 175.2,

156.1, 136.7, 131.3, 126.5, 122.2, 119.7, 118.2, 111.4, 106.8, 60.1, 52.4, 52.0,

51.5, 48.1, 35.6, 32.3, 27.5, 25.1, 22.0, 21.8.

14i: methyl 2-(((4-chlorophenyl)(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)methyl) amino)-3-(1H-indol-3-yl)propanoate

The product was obtained using procedure A, 847 mg, 85 % as colorless liquid;

HRMS (ESI) m/z calcd for C₂₄H₂₈ClN₆O₄ [M+H]⁺ :

499.1855; found: 499.1855; ¹H NMR (500 MHz, CDCl₃)

(*major diastereomer*) δ 8.25 (s, 1H), 7.38-7.30 (m, 2H),

7.27 – 7.17 (m, 4H), 7.06 – 6.95 (m, 2H), 6.90 (s, 1H),

5.23 (s, 1H), 4.63 – 4.55 (m, 2H), 4.43 – 4.33 (m, 1H),

4.12 – 4.05 (m, 1H), 3.74 (s, 3H), 3.39 (s, 3H), 3.30 –

3.20 (m, 4H), 2.99 (dd, *J* = 14.2, 9.4 Hz, 1H); ¹³C NMR (126 MHz, CDCl₃)


(*major diastereomer*) δ 174.1, 156.2, 136.0, 134.9, 134.3, 129.1, 128.7, 126.9,

123.3, 122.4, 119.6, 118.5, 111.3, 110.4, 102.7, 57.7, 55.7, 55.3, 54.3, 52.1,

49.0, 29.4. *diastereomeric ratio* = 3:2

**4i: methyl 4-(4-chlorophenyl)-4,6,7,12,12b,13-hexahydrotetrazolo
[1'',5'':4',5']pyrazino[1',2':1,2]pyrido[3,4-b]indole-6-carboxylate**

The product was obtained using procedure C, 369 mg, 85 % as pale yellow



solid, m.p.: 170-172 °C; HRMS (ESI) m/z calcd for

C₂₂H₂₀N₆O₂ [M+H]⁺ : 435.1331; found: 435.1331; ¹H

NMR (500 MHz, CDCl₃) δ 8.79 (s, 1H), 7.51 (d, *J* = 7.5

Hz, 1H), 7.40 – 7.28 (m, 5H), 7.21 (t, *J* = 7.5 Hz, 1H),

7.14 (t, *J* = 7.5 Hz, 1H), 5.82 (s, 1H), 5.14 (d, *J* = 9.7

Hz, 2H), 4.21 (t, *J* = 12.0 Hz, 1H), 3.82 (d, *J* = 5.0 Hz,

1H), 3.57 (s, 3H), 3.27 (d, *J* = 15.3 Hz, 1H), 3.04 (dd, *J* = 15.3, 5.3 Hz, 1H); ¹³C

NMR (126 MHz, CDCl₃) δ 172.2, 153.8, 136.9, 135.4, 135.3, 129.9, 129.7,

128.7, 126.2, 122.5, 119.7, 118.3, 111.5, 107.4, 60.5, 55.3, 51.9, 51.3, 50.8,

25.0. *diastereomeric ratio* = 9:1

**14j: methyl 2-(((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(phenyl)methyl)
amino)-3-(1H-indol-3-yl)propanoate**

The product was obtained using procedure A, 798 mg, 86 % as white solid,

m.p.: 63-65 °C; HRMS (ESI) m/z calcd for C₂₄H₂₉N₆O₄

[M+H]⁺ : 465.2245; found: 465.2246; ¹H NMR (500

MHz, CDCl₃) (*major diastereomer*) δ 8.32 (s, 1H), 7.38 –

7.25 (m, 3H), 7.20 – 7.14 (m, 2H), 7.13 – 7.06 (m, 2H),

7.04 - 6.98 (m, 2H), 5.29 (s, 1H), 4.54 – 4.46 (m, 2H),

4.34 – 4.27 (m, 1H), 4.07 (dd, *J* = 8.5, 5.5 Hz, 1H), 3.70 (s, 3H), 3.35 (s, 3H),

3.28 (dd, *J* = 14.2, 4.8 Hz, 1H), 3.24 (s, 3H), 3.05 (dd, *J* = 14.4, 8.6 Hz, 1H),

2.68 (brs, 1H); ¹³C NMR (126 MHz, CDCl₃) (*major diastereomer*) δ 174.2,


156.5, 136.5, 136.3, 128.7, 128.4, 127.8, 127.1, 123.3, 122.1, 119.5, 118.5,

111.3, 110.4, 102.5, 59.7, 57.9, 55.4, 55.0, 52.0, 48.9, 29.1. *diastereomeric ratio*

= 2:1

4j: methyl 4-phenyl-4,6,7,12,12b,13-hexahydro-1,2,4-triazolo[1',5'':4',5']pyrazino[1',2':1,2]pyrido[3,4-b]indole-6-carboxylate

The product was obtained using procedure C, 296 mg, 74 % as white solid, m.p.: 165-167 °C; HRMS (ESI) m/z calcd for C₂₂H₂₁N₆O₂




[M+H]⁺ : 401.1721; found: 401.1719; ¹H NMR (500 MHz, CDCl₃) (*major diastereomer*) δ 8.28 (s, 1H), 7.72 (d, *J* = 7.7 Hz, 1H), 7.77-7.30 (m, 5H), 7.25-7.10 (m, 3H), 5.83 (s, 1H), 5.16 (d, *J* = 10.2 Hz, 1H), 5.06 (d, *J* = 12.2 Hz, 1H), 4.34 – 4.22 (m, 1H), 3.89 (d, *J* = 4.9 Hz, 1H), 3.58 (s, 3H), 3.25 (d, *J* = 15.4 Hz, 1H), 3.05 (dd, *J* = 15.4,


5.5 Hz, 1H); ¹³C NMR (126 MHz, CDCl₃) (*major diastereomer*) δ 172.3, 154.2, 136.9, 136.5, 129.3, 129.2, 128.9, 128.6, 126.2, 122.2, 119.5, 118.1, 111.5, 107.2, 61.0, 58.1, 51.6, 51.2, 46.4, 22.6. *diastereomeric ratio* = 2:1

Computational Chemical Descriptors

A virtual library of 100,000 randomly generated compounds were made for each library using previously described methods (Koes, D. et al. PLoS One 2012, 7, e32839.). 1000 compounds of each reaction were randomly selected and physiochemical properties relating to drug likeness were analyzed via ChemAxon's Instant JChem Software (Instant JChem 5.9.2, 2012, ChemAxon <http://www.chemaxon.com>). Principal moment of inertia was calculated using Schrodinger's Maestro V 9.3(Suite 2012: Maestro, version 9.3, Schrödinger, LLC, New York, NY, 2012.)



SI Figure 1: Principal component analysis of our three scaffolds described in this paper and 1000 randomly selected compounds from the zinc database. (Top left) Overlap of all three scaffolds and ZINC compounds. (Top right) Overlap of Scaffold 2 and ZINC database. (Bottom left) Overlap of Scaffold 3 and ZINC database. (Bottom right) Overlap of Scaffold 4 and ZINC database.



SI Figure 2: 3D PCA of 1000 randomly selected compounds of all three scaffolds (green = scaffold 2, blue = scaffold 3, red = scaffold 4).

PCA Data:

Importance of components:

	PC1	PC2	PC3	PC4	PC5	PC6	PC7	PC8	PC9	PC10
Standard deviation	3.6154	2.64	1.9758	1.75386	1.2311	1.14611	1.03285	0.99559	0.81857	0.77989
Proportion of Variance	0.3735	0.1991	0.1115	0.08789	0.0433	0.03753	0.03048	0.02832	0.01914	0.01738
Cumulative Proportion	0.3735	0.5726	0.6841	0.77202	0.8153	0.85285	0.88333	0.91165	0.9308	0.94817

Rotation:

	PC1	PC2	PC3	PC4	PC5	PC6	PC7	PC8	PC9	PC10
Mass	0.0867	0.3379	-0.0188	0.1163	-0.0143	0.0370	-0.0348	0.0192	-0.0048	0.0789
donorcount	-0.0889	0.0742	0.3558	0.1071	-0.3184	0.0217	0.2822	-0.1332	0.0138	-0.2980
donsitecount	-0.0910	0.0719	0.3551	0.1079	-0.3126	0.0202	0.2780	-0.1317	0.0138	-0.3195
acceptorcount	-0.1659	0.2060	0.1546	0.0366	0.0189	0.0657	-0.3990	0.1346	0.0203	0.1570
accsitecount	-0.1748	0.2053	0.1387	0.0547	-0.0156	0.0740	-0.3746	0.1253	0.0202	0.1389
logP	0.1546	0.0694	-0.3528	0.1100	-0.1685	0.0158	0.0958	-0.0545	0.0218	-0.0125
pH0	0.1285	0.0342	-0.1990	0.2709	-0.2378	0.0979	-0.0021	0.0261	0.0104	0.2424
pH7	0.1590	0.0413	-0.3411	0.0611	-0.2063	0.0216	0.0805	-0.0695	0.0234	0.0671
pH14	0.2164	-0.0098	-0.2576	0.0377	0.1031	-0.0268	0.1176	-0.0068	0.0118	-0.0498
PSA	-0.0652	0.1827	0.3486	0.1636	-0.0125	0.0744	-0.0686	0.1056	-0.0160	0.1972
Atomcount	0.0131	0.3490	-0.1024	-0.0430	0.1202	-0.0353	0.1541	-0.0322	0.0043	-0.1359
AliphaticAtomCount	-0.2140	0.1956	-0.0848	-0.1381	0.0694	-0.0189	0.1052	-0.0217	0.0055	0.0325
AromaticAtomCount	0.2455	0.0893	0.0606	0.1780	-0.0738	0.0437	-0.1052	0.0247	-0.0106	0.0010
BondCount	0.0451	0.3496	-0.0839	-0.0591	0.0991	-0.0263	0.1427	-0.0338	-0.0004	-0.1247
AliphaticBond Count	-0.1816	0.2415	-0.0856	-0.1735	0.0576	-0.0046	0.0795	-0.0212	-0.0015	0.0366
AromaticBond Count	0.2478	0.0889	0.0721	0.1655	-0.0779	0.0396	-0.0800	0.0173	-0.0108	0.0028
RotatableBond Count	-0.1641	0.1958	-0.0780	0.2371	0.1640	0.0106	0.1159	-0.0170	-0.0535	0.0260
RingCount	0.2329	0.1592	0.0863	-0.1333	-0.0963	0.0477	-0.0123	-0.0260	-0.0311	0.0191
AliphaticRingCount	-0.0329	0.1499	-0.0199	-0.4976	-0.0762	0.0419	0.0114	-0.0657	-0.0291	-0.0171
AromaticRingCount	0.2527	0.0762	0.0979	0.1446	-0.0542	0.0245	-0.0188	0.0106	-0.0150	0.0288
HeteroRingCount	0.2252	0.0256	0.1907	-0.1291	0.2155	-0.0752	0.1109	0.0286	0.0110	0.1289
HeteroaliphaticRingCount	0.1248	0.1218	0.0887	-0.3805	0.2190	-0.0908	-0.0447	-0.0084	0.0695	-0.0910
HeteroaromaticRingCount	0.2248	-0.0392	0.2005	0.0570	0.1552	-0.0455	0.1746	0.0432	-0.0272	0.2264
RingAtomCount	0.2260	0.1785	0.0185	-0.0772	-0.1504	0.0611	-0.1412	0.0231	-0.0125	0.0054
RingBondCount	0.2272	0.1803	0.0452	-0.1161	-0.1454	0.0427	-0.0894	0.0042	-0.0024	-0.0059
ChainAtomCount	-0.2070	0.1505	-0.0405	0.2166	0.1865	-0.0412	0.1699	-0.0216	0.0078	0.0370
ChainBondCount	-0.1863	0.1793	-0.0626	0.2677	0.1871	-0.0076	0.1163	-0.0043	-0.0176	0.0651
SmallestRingSize	0.0044	0.0478	0.0187	0.0793	-0.0964	-0.6832	-0.0868	-0.0028	0.6961	0.0308
LargestRingSize	-0.1756	0.0788	-0.1144	-0.1618	-0.4112	0.0002	0.0209	0.0360	0.0046	0.2064
RingCountofSize4	-0.0003	-0.0445	0.0118	-0.0576	0.0985	0.6748	0.1512	0.0189	0.7040	0.0590
RingCountofSize5	0.1622	0.0200	0.2161	-0.1284	-0.0077	-0.1114	0.3838	-0.0847	-0.0608	0.5636
RingCountofSize6	0.2365	0.1268	0.0180	0.0046	0.0481	0.0264	-0.2228	0.0196	0.0407	-0.3503
RingCountofSize7	-0.2007	0.0830	-0.0955	-0.1535	-0.3610	0.0079	-0.0496	-0.1125	0.0008	0.1794
RingCountofSize8	-0.0091	0.0023	-0.0413	-0.0694	-0.1296	-0.0479	0.2559	0.9359	-0.0166	-0.1073
VDWVol	0.0458	0.3619	-0.0857	0.0467	0.0585	-0.0033	0.0647	-0.0094	0.0020	-0.0511

Single Crystal X-Ray Structure Determination of Compounds **3C**, **2E** and **4F**

General:

Data were collected on an X-ray single crystal diffractometer equipped with a CCD detector (APEX II, κ -CCD), a rotating anode (Bruker AXS, FR591) with MoK $_{\alpha}$ radiation ($\lambda = 0.71073 \text{ \AA}$) and a MONTEL-type focusing optic (compound **4F**) or a fine-focussed sealed tube (Bruker AXS, D8), respectively (compounds **3C** and **2E**) and a graphite monochromator by using the SMART software package. [1] The measurements were performed on single crystals coated with perfluorinated ether. The crystals were fixed on the top of a cactus prickle (*Opuntia ficus-india*) and transferred to the diffractometer. The crystals were frozen under a stream of cold nitrogen. A matrix scan was used to determine the initial lattice parameters. Reflections were merged and corrected for Lorenz and polarization effects, scan speed, and background using SAINT. [2] Absorption corrections, including odd and even ordered spherical harmonics were performed using SADABS. [2] Space group assignments were based upon systematic absences, *E* statistics, and successful refinement of the structures. Structures were solved by direct methods with the aid of successive difference Fourier maps, and were refined against all data using WinGX [7] based on SIR-92. [3] If not mentioned otherwise, non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms could be located in the difference Fourier maps and were allowed to refine freely (compounds **2E** and **4F**). Unless otherwise noticed, methyl hydrogen atoms were refined as part of rigid rotating groups, with a C–H distance of 0.98 \AA and $U_{\text{iso(H)}} = 1.5 \cdot U_{\text{eq(C)}}$. Other H atoms were placed in calculated positions and refined using a riding model, with methyne, methylene and aromatic C–H distances of 1.00, 0.99 and 0.95 \AA , respectively, and $U_{\text{iso(H)}} = 1.2 \cdot U_{\text{eq(C)}}$. (compound **3C**). Full-matrix least-squares refinements were carried out by minimizing $\sum w(F_o^2 - F_c^2)^2$ with

SHELXL-97 [5] weighting scheme. Neutral atom scattering factors for all atoms and anomalous dispersion corrections for the non-hydrogen atoms were taken from *International Tables for Crystallography*. [4] Images of the crystal structures were generated by PLATON. [6] CCDC 1017121 (**2E**), CCDC 1017122 (**4F**), and CCDC 1017123 (**3C**) contains the supplementary crystallographic data for this compound. This data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif or via https://www.ccdc.cam.ac.uk/services/structure_deposit/

Special:

- 3C:** Full refinement was possible without running into problems.
The hydrogen atom bound to N5 was allowed to refine freely.
- 2E:** Full refinement was possible without running into problems.
- 4F:** Full refinement was possible without running into problems.
Small extinction effects were cured with the SHELXL procedure.

Compound 3C




Figure F1 – Ortep drawing of compound **3C** with 50% ellipsoids. [6]

Operator:	*** Herdtweck ***
Molecular Formula:	C ₂₀ H ₂₀ Cl N ₅ O ₃
Crystal Color / Shape	Colorless fragment
Crystal Size	Approximate size of crystal fragment used for data collection: 0.10 × 0.25 × 0.33 mm
Molecular Weight:	413.86 a.m.u.
F ₀₀₀ :	432
Systematic Absences:	none
Space Group:	Triclinic $P\bar{1}$ (I.T.-No.: 2)

Cell Constants: Least-squares refinement of 9874 reflections with the programs "APEX suite" and "SAINT" [1,2]; theta range $1.84^\circ < \theta < 25.38^\circ$; Mo($K\bar{\alpha}$); $\lambda = 0.71073 \text{ \AA}$

$a = 9.7930(3) \text{ \AA}$ $\alpha = 76.4624(14)^\circ$
 $b = 10.1156(3) \text{ \AA}$ $\beta = 89.7725(14)^\circ$
 $c = 11.4745(3) \text{ \AA}$ $\gamma = 61.9039(15)^\circ$

$V = 967.37(5) \cdot \text{\AA}^3$; $Z = 2$; $D_{\text{calc}} = 1.421 \text{ g cm}^{-3}$; Mos. = 0.77

Diffractometer: Kappa APEX II (Area Diffraction System; BRUKER AXS); sealed tube; graphite monochromator; 50 kV; 30 mA; $\lambda = 0.71073 \text{ \AA}$; Mo($K\bar{\alpha}$)

Temperature: $(-150 \pm 1)^\circ\text{C}$; $(123 \pm 1) \text{ K}$

Measurement Range: $1.84^\circ < \theta < 25.38^\circ$; h: -11/11, k: -12/12, l: -13/13

Measurement Time: $2 \times 15 \text{ s per film}$

Measurement Mode: measured: 7 runs; 1698 films / scaled: 7 runs; 1698 films

φ - and ω -movement; Increment: $\Delta\varphi/\Delta\omega = 1.00^\circ$; dx = 40.0 mm

LP - Correction: Yes [2]

Intensity Correction: No/Yes; during scaling [2]

Absorption Correction: Multi-scan; during scaling; $\mu = 0.231 \text{ mm}^{-1}$ [2]

Correction Factors: $T_{\text{min}} = 0.7056$ $T_{\text{max}} = 0.7452$

Reflection Data: 28405 reflections were integrated and scaled

28405 reflections to be merged

3553 independent reflections

0.022 R_{int} : (basis F_o^2)

3553 independent reflections (all) were used in refinements

3077 independent reflections with $I_o > 2\sigma(I_o)$

99.7 % completeness of the data set

269 parameter full-matrix refinement

13.2 reflections per parameter

Solution:	Direct Methods [3, 7]; Difference Fourier syntheses	
Refinement Parameters:	In the asymmetric unit:	
	29	Non-hydrogen atoms with anisotropic displacement parameters
	1	Hydrogen atoms with isotropic displacement parameters
Hydrogen Atoms:	The N-hydrogen atom positions was found in the difference and was refined with an individual isotropic displacement parameters.	
Hydrogen Atoms:	All other hydrogen atoms were placed in calculated positions ($d_{C-H} = 0.95, 0.98, 0.99, 1.00 \text{ \AA}$). Isotropic displacement parameters were calculated from the parent carbon atom ($U_H = 1.2/1.5 U_C$). The hydrogen atoms were included in the structure factor calculations but not refined.	
Atomic Form Factors:	For neutral atoms and anomalous dispersion [4, 5, 7]	
Extinction Correction:	no	
Weighting Scheme:	$w^{-1} = \sigma^2(F_o^2) + (a * P)^2 + b * P$ with a: 0.0435; b: 1.8951; P: $[\text{Maximum}(0 \text{ or } F_o^2) + 2 * F_c^2] / 3$	
Shift/Err:	Less than 0.001 in the last cycle of refinement:	
Resid. Electron Density:	$+1.07 \text{ e}_0^- / \text{\AA}^3$; $-0.66 \text{ e}_0^- / \text{\AA}^3$	
R1:	$\sum(F_o - F_c) / \sum F_o $	
$[F_o > 4\sigma(F_o)$; N=3077]:		= 0.0584
[all reflctns; N=3553]:		= 0.0672
wR2:	$[\sum w(F_o^2 - F_c^2)^2 / \sum w(F_o^2)^2]^{1/2}$	
$[F_o > 4\sigma(F_o)$; N=3077]:		= 0.1347
[all reflctns; N=3553]:		= 0.1406
Goodness of fit:	$[\sum w(F_o^2 - F_c^2)^2 / (\text{NO} - \text{NV})]^{1/2} = 1.064$	
Remarks:	Refinement expression $\sum w(F_o^2 - F_c^2)^2$	

Compound 2E




Figure F2 – Ortep drawing of compound **2E** with 50% ellipsoids. [6]

Operator:	*** Herdtweck ***
Molecular Formula:	C ₁₇ H ₂₁ N ₅
Crystal Color / Shape	Colorless fragment
Crystal Size	Approximate size of crystal fragment used for data collection: 0.30 × 0.30 × 0.30 mm
Molecular Weight:	295.39 a.m.u.
F ₀₀₀ :	632
Systematic Absences:	h0l: h+l≠2n; 0k0: k≠2n
Space Group:	Monoclinic <i>P</i> 2 ₁ / <i>n</i> (I.T.-No.: 14)

Cell Constants: Least-squares refinement of 9927 reflections with the programs "APEX suite" and "SAINT" [1,2]; theta range $2.14^\circ < \theta < 25.39^\circ$; Mo($K\bar{\alpha}$); $\lambda = 0.71073 \text{ \AA}$

$a = 8.2232(2) \text{ \AA}$

$b = 15.4975(5) \text{ \AA}$ $\beta = 104.8288(12)^\circ$

$c = 12.4813(4) \text{ \AA}$

$V = 1537.63(8) \cdot \text{\AA}^3$; $Z = 4$; $D_{\text{calc}} = 1.276 \text{ g cm}^{-3}$; Mos. = 0.63

Diffractometer: Kappa APEX II (Area Diffraction System; BRUKER AXS); sealed tube; graphite monochromator; 50 kV; 30 mA; $\lambda = 0.71073 \text{ \AA}$; Mo($K\bar{\alpha}$)

Temperature: $(-150 \pm 1)^\circ \text{C}$; $(123 \pm 1) \text{ K}$

Measurement Range: $2.14^\circ < \theta < 25.39^\circ$; h: -9/9, k: -18/18, l: -14/15

Measurement Time: $2 \times 10 \text{ s}$ per film

Measurement Mode: measured: 12 runs; 3494 films / scaled: 12 runs; 3494 films

φ - and ω -movement; Increment: $\Delta\varphi/\Delta\omega = 0.50^\circ$; dx = 35.0 mm

LP - Correction: Yes [2]

Intensity Correction: No/Yes; during scaling [2]

Absorption Correction: Multi-scan; during scaling; $\mu = 0.080 \text{ mm}^{-1}$ [2]

Correction Factors: $T_{\text{min}} = 0.6914$ $T_{\text{max}} = 0.7452$

Reflection Data: 59840 reflections were integrated and scaled

1408 reflections systematic absent and rejected

58432 reflections to be merged

2820 independent reflections

0.027 R_{int} : (basis F_o^2)

2820 independent reflections (all) were used in refinements

2610 independent reflections with $I_o > 2\sigma(I_o)$

99.9 % completeness of the data set

283 parameter full-matrix refinement

10.0 reflections per parameter

Solution: Direct Methods [3, 7]; Difference Fourier syntheses

Refinement Parameters: In the asymmetric unit:

22 Non-hydrogen atoms with anisotropic displacement parameters

21 Hydrogen atoms with isotropic displacement parameters

Hydrogen Atoms: All hydrogen atom positions were found in the difference map calculated from the model containing all non-hydrogen atoms. The hydrogen positions were refined with individual isotropic displacement parameters.

Atomic Form Factors: For neutral atoms and anomalous dispersion [4, 5, 7]

Extinction Correction: no

Weighting Scheme: $w^{-1} = \sigma^2(F_o^2) + (a * P)^2 + b * P$
with a: 0.0441; b: 0.6040; P: [Maximum(0 or F_o^2) + 2 * F_c^2]/3

Shift/Err: Less than 0.001 in the last cycle of refinement:

Resid. Electron Density: +0.25 e₀ / Å³; -0.18 e₀ / Å³

R1: $\sum(|F_o| - |F_c|) / \sum|F_o|$

[$F_o > 4\sigma(F_o)$; N=2610]: = 0.0338

[all reflctns; N=2820]: = 0.0368

wR2: $[\sum w(F_o^2 - F_c^2)^2 / \sum w(F_o^2)^2]^{1/2}$

[$F_o > 4\sigma(F_o)$; N=2610]: = 0.0873

[all reflctns; N=2820]: = 0.0901

Goodness of fit: $[\sum w(F_o^2 - F_c^2)^2 / (NO - NV)]^{1/2}$ = 1.056

Remarks: Refinement expression $\sum w(F_o^2 - F_c^2)^2$

Compound 4F




Figure F3– Ortep drawing of compound **4F** with 50% ellipsoids. [6]

Operator:	*** Herdtweck ***
Molecular Formula:	C ₂₇ H ₃₃ N ₇ O (C ₂₅ H ₂₇ N ₇), (C ₂ H ₆ O)
Crystal Color / Shape	Colorless plate
Crystal Size	Approximate size of crystal fragment used for data collection: 0.11 × 0.26 × 0.35 mm
Molecular Weight:	471.60 a.m.u.
F ₀₀₀ :	504
Systematic Absences:	none
Space Group:	Triclinic $P\bar{1}$ (I.T.-No.: 2)
Cell Constants:	Least-squares refinement of 9987 reflections with the programs "APEX suite" and "SAINT" [1,2]; theta range 1.42° < θ < 25.45°; Mo(K α); λ = 71.073 pm

$a = 858.12(6) \text{ pm}$ $\alpha = 86.569(3)^\circ$
 $b = 1014.11(7) \text{ pm}$ $\beta = 89.634(3)^\circ$
 $c = 1431.89(10) \text{ pm}$ $\gamma = 79.327(3)^\circ$
 $V = 1222.31(15) \cdot 10^6 \text{ pm}^3$; $Z = 2$; $D_{\text{calc}} = 1.281 \text{ g cm}^{-3}$; Mos. = 0.63

Diffractometer: Kappa APEX II (Area Diffraction System; BRUKER AXS); rotating anode; graphite monochromator; 50 kV; 60 mA; $\lambda = 71.073 \text{ pm}$; Mo(K $\bar{\alpha}$)

Temperature: $(-173 \pm 1)^\circ \text{C}$; $(100 \pm 1) \text{ K}$

Measurement Range: $1.42^\circ < \theta < 25.45^\circ$; h: -10/10, k: -12/12, l: -17/17

Measurement Time: $2 \times 5 \text{ s}$ per film

Measurement Mode: measured: 15 runs; 6018 films / scaled: 15 runs; 6018 films
 φ - and ω -movement; Increment: $\Delta\varphi/\Delta\omega = 0.50^\circ$; dx = 35.0 mm

LP - Correction: Yes [2]

Intensity Correction No/Yes; during scaling [2]

Absorption Correction: Multi-scan; during scaling; $\mu = 0.082 \text{ mm}^{-1}$ [2]

Correction Factors: $T_{\text{min}} = 0.7027$ $T_{\text{max}} = 0.7452$

Reflection Data: 30230 reflections were integrated and scaled
 30230 reflections to be merged
 4504 independent reflections
 0.028 R_{int} : (basis F_o^2)
 4504 independent reflections (all) were used in refinements
 4167 independent reflections with $I_o > 2\sigma(I_o)$
 99.5 % completeness of the data set
 449 parameter full-matrix refinement
 10.0 reflections per parameter

Solution: Direct Methods [3]; Difference Fourier syntheses

Refinement Parameters: In the asymmetric unit:



35	Non-hydrogen atoms with anisotropic displacement parameters
33	Hydrogen atoms with isotropic displacement parameters
Hydrogen Atoms:	All hydrogen atom positions were found in the difference map calculated from the model containing all non-hydrogen atoms. The hydrogen positions were refined with individual isotropic displacement parameters.
Atomic Form Factors:	For neutral atoms and anomalous dispersion [4]
Extinction Correction:	$F_c(\text{korr}) = kF_c[1 + 0.001 \cdot \varepsilon \cdot F_c^2 \cdot \lambda^3 / \sin(2\theta)]^{-1/4}$ SHELXL-97 [5] ε refined to $\varepsilon = 0.014(2)$
Weighting Scheme:	$w^{-1} = \sigma^2(F_o^2) + (a \cdot P)^2 + b \cdot P$ with a: 0.0368; b: 0.6392; P: $[\text{Maximum}(0 \text{ or } F_o^2) + 2 \cdot F_c^2] / 3$
Shift/Err:	Less than 0.001 in the last cycle of refinement:
Resid. Electron Density:	+0.28 e ₀ ⁻ /Å ³ ; -0.22 e ₀ ⁻ /Å ³
R1:	$\sum(F_o - F_c) / \sum F_o $
[F _o > 4σ(F _o); N=4167]:	= 0.0357
[all reflctns; N=4504]:	= 0.0385
wR2:	$[\sum w(F_o^2 - F_c^2)^2 / \sum w(F_o^2)^2]^{1/2}$
[F _o > 4σ(F _o); N=4167]:	= 0.0882
[all reflctns; N=4504]:	= 0.0909
Goodness of fit:	$[\sum w(F_o^2 - F_c^2)^2 / (\text{NO} - \text{NV})]^{1/2}$ = 1.057
Remarks:	Refinement expression $\sum w(F_o^2 - F_c^2)^2$

Crystal Structure References:

- [1] APEX suite of crystallographic software. APEX 2 Version 2008.4. Bruker AXS Inc., Madison, Wisconsin, USA (2008).
- [2] SAINT, Version 7.56a and SADABS Version 2008/1. Bruker AXS Inc., Madison, Wisconsin, USA (2008).

- [3] Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.; Burla, M. C.; Polidori, G.; Camalli M. "**SIR92**", *J. Appl. Cryst.* **1994**, *27*, 435-436.
- [4] International Tables for Crystallography, Vol. C, Tables 6.1.1.4 (pp. 500-502), 4.2.6.8 (pp. 219-222), and 4.2.4.2 (pp. 193-199), Wilson, A. J. C., Ed., Kluwer Academic Publishers, Dordrecht, The Netherlands, 1992.
- [5] Sheldrick, G. M. "**SHELXL-97**", University of Göttingen, Göttingen, Germany, (1998).
- [6] Spek, A. L. "**PLATON**", A Multipurpose Crystallographic Tool, Utrecht University, Utrecht, The Netherlands, (2010).
- [7] L. J. Farrugia, "**WinGX** (Version 1.70.01 January 2005) ", *J. Appl. Cryst.* **1999**, *32*, 837-838.


8a: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(4-nitrophenyl)methyl)-2-(4-methoxyphenyl)ethanamine



PHP072_1_Silica_4.6X250_MeOH_5-30%_6min


PHP072_1

3: Diode Array
Range: 5.51e+1



PHP072_1


2: Scan ES-
441.2
1.11e7





PHP072_1_Silica_4.6X250_MeOH_5-30%_6min

PHP072_1 168 (2.917)

2: Scan ES-
5.28e6




2a: 7-(4-methoxyphenethyl)-8-(4-nitrophenyl)-7,8-dihydro-1,5-benzodiazepine.




PHP077_1_Silica_4.6X250_MeOH_5-30%_6min
PHP077_1

3: Diode Array
Range: 3.295e+1





PHP077_1

2: Scan ES-
377.14
3.81e6




PHP077_1_Silica_4.6X250_MeOH_5-30%_6min
PHP077_1 183 (3.178)

2: Scan ES-
2.41e6




Chemical Formula: C₁₉H₁₈N₆O₃
Exact Mass: 378.14

8b: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(4-nitrophenyl)methyl)propan-1-amine.




PHP233_1_Silica_4.6X250_MeOH_5-30%_6
PHP233_1

3: Diode Array
Range: 1.866e+1





PHP233_1

2: Scan ES-
349
6.55e6




PHP233_1_Silica_4.6X250_MeOH_5-30%_6
PHP233_1 140 (2.431)

2: Scan ES-
4.23e6



Chemical Formula: C₁₅H₂₂N₆O₄
Exact Mass: 350.17
Molecular Weight: 350.37


2b: 8-(4-nitrophenyl)-7-propyl-7,8-dihydro-1,5-a-pyrazine.



PHP246_1_Silica_4.6X250_MeOH_5-30%_6


PHP246_1

3: Diode Array
Range: 2.722e+1



PHP246_1



1: Scan ES+
287
2.85e7



PHP246_1_Silica_4.6X250_MeOH_5-30%_6


PHP246_1 168 (2.909)

1: Scan ES+
2.59e7



Chemical Formula: C₁₃H₁₄N₆O₂
Exact Mass: 286,12
Molecular Weight: 286,29


8c: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(4-methoxyphenyl)methyl)propan-1-amine.



PHP193_1_Silica_4.6X250_MeOH_5-30%_6


PHP193_1

3: Diode Array
Range: 5.617



PHP193_1


1: Scan ES+
336
4.15e7




PHP193_1_Silica_4.6X250_MeOH_5-30%_6

PHP193_1 147 (2.544)

1: Scan ES+
8.10e7




2c: 8-(4-methoxyphenyl)-7-propyl-7,8-dihydro-1,5-benzodiazepine.



PHP196_1_silica_4.6x250_sol1_5-30%_6min


PHP196_1R

3: Diode Array
Range: 2.855e+1



PHP196_1R



1: Scan ES+
272
9.81e5



PHP196_1_silica_4.6x250_sol1_5-30%_6min

PHP196_1R 147 (2.544)

1: Scan ES+
7.35e6




Chemical Formula: C₁₄H₁₇N₅O

Exact Mass: 271,14

Molecular Weight: 271,32


8d: N-(1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)cyclohexyl)aniline.



PHP138_1_Silica_4.6X250_MeOH_5-30%_6


PHP138_1

3: Diode Array
Range: 9.455



PHP138_1



2: Scan ES-
330
2.69e6



PHP138_1_Silica_4.6X250_MeOH_5-30%_6


PHP138_1 141 (2.448)

2: Scan ES-
1.55e6



Chemical Formula: C₁₇H₂₅N₅O₂
Exact Mass: 331.20
Molecular Weight: 331.41


2d: 7'-phenyl-7'H-spiro[cyclohexane-1,8'-tetrazolo[1,5-a]pyrazine].



PHP142_1_Silica_4.6X250_MeOH_5-30%_6


PHP142_1

3: Diode Array
Range: 5.336



PHP142_1


1: Scan ES+
268
5.57e7





PHP142_1_Silica_4.6X250_MeOH_5-30%_6

PHP142_1 135 (2.336)

1: Scan ES+
4.18e7




8e: N-(1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)cyclohexyl)-2,4-dimethylaniline.



PHP140_1_Silica_4.6X250_MeOH_5-30%_6


PHP140_1

3: Diode Array
Range: 5.807





PHP140_1

1: Scan ES+
360
5.90e5




PHP140_1 128 (2.223)

2: Scan ES-
1.22e5



Chemical Formula: C₁₉H₂₉N₅O₂
Exact Mass: 359,23
Molecular Weight: 359,47


2e: 7'-(2,4-dimethylphenyl)-7'H-spiro[cyclohexane-1,8'-tetrazolo[1,5-a]pyrazine].



PHP148_1_Silica_4.6X250_MeOH_5-30%_6


PHP148_1

3: Diode Array
Range: 6.66



PHP148_1



1: Scan ES+
296
4.00e7



PHP148_1_Silica_4.6X250_MeOH_5-30%_6


PHP148_1 127 (2.197)

1: Scan ES+
3.88e7



Chemical Formula: C₁₇H₂₁N₅
Exact Mass: 295,1797
Molecular Weight: 295,3821


8f: N-(1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)cyclohexyl)-2,6-dimethylaniline.



PHP143_1_Silica_4.6X250_MeOH_5-30%_6


PHP143_1

3: Diode Array
Range: 5.815



PHP143_1



1: Scan ES+
360
9.83e5




PHP143_1_Silica_4.6X250_MeOH_5-30%_6

PHP143_1 125 (2.162)

1: Scan ES+
3.13e6





2f: 7'-(2,6-dimethylphenyl)-7'H-spiro[cyclohexane-1,8'-tetrazolo[1,5-a]pyrazine].





PHP150_1_Silica_4.6X250_MeOH_5-30%_6
PHP150_1

3: Diode Array
Range: 1.546e+1




PHP150_1_Silica_4.6X250_MeOH_5-30%_6
PHP150_1 126 (2.179)

1: Scan ES+
2.59e7



Chemical Formula: C₁₇H₂₁N₅
Exact Mass: 295,1797
Molecular Weight: 295,3821


8g: N-(1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)cyclohexyl)pyridin-2-amine.




PHP245_1_Silica_4.6X250_MeOH_5-30%_6

PHP245_1

3: Diode Array
Range: 1.562e+1



PHP245_1





1: Scan ES+
333
8.44e7

PHP245_1_Silica_4.6X250_MeOH_5-30%_6


PHP245_1 158 (2.735)

1: Scan ES+
7.40e7



Chemical Formula: C₁₆H₂₄N₆O₂
Exact Mass: 332.20
Molecular Weight: 332.40


2g: 7'-(pyridin-2-yl)-7'H-spiro[cyclohexane-1,8'-tetrazolo[1,5-a]pyrazine].



PHP259_1_Silica_4.6X250_MeOH_5-30%_6


PHP259_1

3: Diode Array
Range: 2.564e+1



PHP259_1



1: Scan ES+
269
8.19e7



PHP259_1_Silica_4.6X250_MeOH_5-30%_6


PHP259_1 183 (3.169)

1: Scan ES+
7.54e7




Chemical Formula: C₁₄H₁₆N₆
Exact Mass: 268,1436
Molecular Weight: 268,3170

8h: 1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)-N-phenethylpropan-1-amine.




PHP238_1_Silica_4.6X250_MeOH_5-30%_6
PHP238_1

3: Diode Array
Range: 1.892





PHP238_1

1: Scan ES+
320
4.98e7






PHP238_1_Silica_4.6X250_MeOH_5-30%_6
PHP238_1 142 (2.457)

1: Scan ES+
4.98e7



Chemical Formula:
C₁₆H₂₅N₅O₂
Exact Mass: 319,20
Molecular Weight: 319,40


2h: 8-ethyl-7-phenethyl-7,8-dihydro-1,5-benzodiazepine.



PHP250_1_Silica_4.6X250_MeOH_5-30%_6


PHP250_1

3: Diode Array
Range: 4.74



PHP250_1



1: Scan ES+
256
3.32e7



PHP250_1_Silica_4.6X250_MeOH_5-30%_6


PHP250_1 148 (2.561)

1: Scan ES+
3.32e7



Chemical Formula:
C₁₄H₁₇N₅
Exact Mass: 255,15
Molecular Weight: 255,32


8i: N-(1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)propyl)butan-1-amine.



PHP145_1_Silica_4.6X250_MeOH_5-30%_6


PHP145_1

3: Diode Array
Range: 1.722



PHP145_1



1: Scan ES+
272
8.33e7



PHP145_1_Silica_4.6X250_MeOH_5-30%_6



PHP145_1 128 (2.214)

1: Scan ES+
8.33e7



Chemical Formula: C₁₂H₂₅N₅O₂
Exact Mass: 271,20
Molecular Weight: 271,36


2i: 7-butyl-8-ethyl-7,8-dihydro-1,5-a-pyrazine.



PHP152_1_Silica_4.6X250_MeOH_5-30%_6


PHP152_1

3: Diode Array
Range: 1.898





PHP152_1


1: Scan ES+
208
1.46e6



4.09e6




11a: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methyl)propan-2-amine.



PHP086_1_Silica_4.6X250_MeOH_5-30%_6min


PHP086_1

3: Diode Array
Range: 4.065e+1





PHP086_1

1: Scan ES+
396.22
6.25e6




PHP086_1 155 (2.683) Cm (153:169)

1: Scan ES+
8.61e7



Chemical Formula:
C₁₈H₂₉N₅O₅
Exact Mass: 395.22


3a: N-isopropyl-7,8,9-trimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine



PHP098_1_Silica_4.6X250_MeOH_5-30%_6min


PHP098_1

3: Diode Array
Range: 9.215e+1




PHP098_1

1: Scan ES+
332.16
1.10e7




PHP098_1 186 (3.221)

1: Scan ES+
1.83e7




11b: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methyl)-N-propylpropan-1-amine.



PHP211_1_Silica_4.6X250_MeOH_5-30%_6


PHP211_1

3: Diode Array
Range: 2.337e+1



PHP211_1



2: Scan ES-
436.5
1.11e5



PHP211_1_Silica_4.6X250_MeOH_5-30%_6

PHP211_1 129 (2.240)

2: Scan ES-
1.01e5





Chemical Formula: $C_{21}H_{35}N_5O_5$

Exact Mass: 437.26

Molecular Weight: 437.53


3b: 7,8,9-trimethoxy-N,N-dipropyl-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.



PHP214_1_Silica_4.6X250_MeOH_5-30%_6


PHP214_1

3: Diode Array
Range: 2.886e+1



PHP214_1


1: Scan ES+
374
1.28e6





PHP214_1_Silica_4.6X250_MeOH_5-30%_6

PHP214_1 120 (2.075)

1: Scan ES+
8.29e7




11c: N-(4-chlorobenzyl)-1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)-1-(3,4,5-trimethoxyphenyl)methanamine.



PHP213_1_Silica_4.6X250_MeOH_5-30%_6


PHP213_1

3: Diode Array
Range: 1.388e+1



PHP213_1



1: Scan ES+
478
8.00e6



PHP213_1_Silica_4.6X250_MeOH_5-30%_6



PHP213_1 162 (2.805)

1: Scan ES+
7.57e7



Chemical Formula: C₂₂H₂₈ClN₅O₅
Exact Mass: 477,18
Molecular Weight: 477,94


3c: N-(4-chlorobenzyl)-7,8,9-trimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.



PHP267_1_Silica_4.6X250_MeOH_5-30%_6


PHP267_1

3: Diode Array
Range: 1.423e+1



PHP267_1



2: Scan ES-
412
3.17e5



PHP267_1_Silica_4.6X250_MeOH_5-30%_6


PHP267_1 158 (2.744)

2: Scan ES-
1.55e5



Chemical Formula: C₂₀H₂₀ClN₅O₃
Exact Mass: 413,1255
Molecular Weight: 413,8575


11d: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methyl) prop-2-en-1-amine.



PHP271_1_Silica_4.6X250_MeOH_5-30%_6


PHP271_1

3: Diode Array
Range: 1.359e+1



PHP271_1



1: Scan ES+
394
3.68e7



PHP271_1_Silica_4.6X250_MeOH_5-30%_6



PHP271_1 152 (2.631)

1: Scan ES+
8.45e7



Chemical Formula: C₁₈H₂₇N₅O₅
Exact Mass: 393,2012
Molecular Weight: 393,4375


3d: N-allyl-7,8,9-trimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.




PHP215_1_Silica_4.6X250_MeOH_5-30%_6

PHP215_1

3: Diode Array
Range: 8.128e+1



PHP215_1





2: Scan ES-
328
2.23e5

PHP215_1_Silica_4.6X250_MeOH_5-30%_6


PHP215_1 149 (2.587)

2: Scan ES-
1.23e5



Chemical Formula: C₁₆H₁₉N₅O₃
Exact Mass: 329,1488
Molecular Weight: 329,3538


11e: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,5-dimethoxyphenyl)methyl)prop-2-en-1-amine.




PHP298_1_Silica_4.6X250_MeOH_5-30%_6

PHP298_1

3: Diode Array
Range: 1.234e+1



PHP298_1





1: Scan ES+
364
7.45e7


PHP298_1_Silica_4.6X250_MeOH_5-30%_6

PHP298_1 139 (2.405)

1: Scan ES+
7.94e7




3e: N-allyl-7,9-dimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.




PHP306_1_Silica_4.6X250_MeOH_5-30%_6

PHP306_1

3: Diode Array
Range: 2.281e+1



PHP306_1





1: Scan ES+
300
2.76e7

PHP306_1_Silica_4.6X250_MeOH_5-30%_6

PHP306_1 149 (2.579)

1: Scan ES+
5.57e7




Chemical Formula: C₁₅H₁₇N₅O₂

Exact Mass: 299,14

Molecular Weight: 299,33


11f: 2-(3-chlorophenyl)-N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,5-dimethoxyphenyl)methyl)ethanamine.



PHP299_1_Silica_4.6X250_MeOH_5-30%_6

PHP299



3: Diode Array
Range: 7.903




PHP299_1_Silica_4.6X250_MeOH_5-30%_6

PHP299 151 (2.622)

2: Scan ES-
1.93e5




3f: N-(3-chlorophenethyl)-7,9-dimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.



PHP307_1_Silica_4.6X250_MeOH_5-30%_6


PHP307_1

3: Diode Array
Range: 2.44e+1



PHP307_1



2: Scan ES-
396
1.44e5



PHP307_1_Silica_4.6X250_MeOH_5-30%_6


PHP307_1 170 (2.952)

2: Scan ES-
1.04e5



Chemical Formula: C₂₀H₂₀ClN₅O₂
Exact Mass: 397,13
Molecular Weight: 397,86


11g: 4-benzyl-1-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,5-dimethoxyphenyl)methyl)piperidine.



PHP297_1_Silica_4.6X250_MeOH_5-30%_6


PHP297_1

3: Diode Array
Range: 9.746



PHP297_1


1: Scan ES+
483
2.35e7




PHP297_1_Silica_4.6X250_MeOH_5-30%_6

PHP297_1 145 (2.509)

1: Scan ES+
5.44e7




3g: 11-(4-benzylpiperidin-1-yl)-7,9-dimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepine.



PHP305_1_Silica_4.6X250_MeOH_5-30%_6


PHP305_1

3: Diode Array
Range: 9.149



PHP305_1


1: Scan ES+
419.5
7.12e6





PHP305_1_Silica_4.6X250_MeOH_5-30%_6

PHP305_1 154 (2.666)

1: Scan ES+
1.70e7







11h: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,5-dimethoxyphenyl)methyl)aniline.





PHP300_1_Silica_4.6X250_MeOH_5-30%_6
PHP300_1

3: Diode Array
Range: 2.085e+1




3h: 7,9-dimethoxy-N-phenyl-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.



PHP308_1_Silica_4.6X250_MeOH_5-30%_6


PHP308_1

3: Diode Array
Range: 8.077



PHP308_1



2: Scan ES-
334
7.62e5



PHP308_1_Silica_4.6X250_MeOH_5-30%_6



PHP308_1 160 (2.778)

2: Scan ES-
3.58e5



Chemical Formula: C₁₈H₁₇N₅O₂
Exact Mass: 335,14
Molecular Weight: 335,36


11i: 2-(3-chlorophenyl)-N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,4-dimethoxyphenyl)methyl)ethanamine.



PHP295_1_Silica_4.6X250_MeOH_5-30%_6


PHP295_1

3: Diode Array
Range: 2.567e+1



PHP295_1



2: Scan ES-
460
2.61e5





PHP295_1_Silica_4.6X250_MeOH_5-30%_6

PHP295_1 171 (2.969)

2: Scan ES-
1.49e5




3i: N-(3-chlorophenethyl)-8,9-dimethoxy-11H-benzo[d]tetrazolo[1,5-a]azepin-11-amine.



PHP303_1_Silica_4.6X250_MeOH_5-30%_6


PHP303_1

3: Diode Array
Range: 4.009e+1



PHP303_1



2: Scan ES-
396
1.72e5



PHP303_1_Silica_4.6X250_MeOH_5-30%_6



PHP303_1 194 (3.369)

2: Scan ES-
1.07e5



Chemical Formula: C₂₀H₂₀ClN₅O₂
Exact Mass: 397.13
Molecular Weight: 397.86


11j: 4-benzyl-1-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,4-dimethoxyphenyl)methyl) piperidine.



PHP294_1_Silica_4.6X250_MeOH_5-30%_6


PHP294_1

3: Diode Array
Range: 2.413e+1



PHP294_1



1: Scan ES+
483
1.26e7






PHP294_1_Silica_4.6X250_MeOH_5-30%_6

PHP294_1 164 (2.839)

1: Scan ES+
3.88e7




3j: 11-(4-benzylpiperidin-1-yl)-8,9-dimethoxy-11H-benzo[d]tetrazolo[1,5-a]zepine.



PHP302_A_1_Silica_4.6X250_MeOH_5-30%_6


PHP302_A_1

3: Diode Array
Range: 3.952e+1





PHP302_A_1

1: Scan ES-
41
1.15e





PHP302_A_1 165 (2.865)

2: Scan ES-
4.52e4




14a: 1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)-N-(3,4-dimethoxyphenethyl)-2-methylpropan-1-amine



PHP091_1_Silica_4.6X250_MeOH_5-30%_6min


PHP091_1

3: Diode Array
Range: 2.323e+1





PHP091_1

1: Scan ES+
394.24
1.37e7





PHP091_1 162 (2.804)

1: Scan ES+
8.89e7



Chemical Formula: C₁₉H₃₁N₅O₄
Exact Mass: 393.24


4a: 8-isopropyl-2,3-dimethoxy-6,8,13,13a-tetrahydro-5H-tetrazolo[1',5':4,5]pyrazino[2,1-a]isoquinoline



PHP112_1_Silica_4.6X250_MeOH_5-30%_6min


PHP112_1

3: Diode Array
Range: 4.835





PHP112_1

1: Scan ES+
330.19
1.11e7




PHP112_1 176 (3.048)

1: Scan ES+
7.56e7



Chemical Formula: C₁₇H₂₃N₅O₂
Exact Mass: 329,19
Molecular Weight: 329,40


14b: N-((4-chlorophenyl)(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)methyl)-2-(3,4-dimethoxyphenyl)ethanamine



PHP027_1_Silica_4.6X250_MeOH_5-30%_6min


PHP027_1 Sm (Mn, 2x3)

1: Scan ES+
462.18
5.41e7
Area





PHP027_1

1: Scan ES+
462.18
6.76e7




PHP027_1 179 (3.100)

1: Scan ES+
8.20e7



Chemical Formula: C₂₂H₂₈ClN₅O₄
Exact Mass: 461.18



4b: 8-(4-chlorophenyl)-2,3-dimethoxy-6,8,13,13a-tetrahydro-5H-tetrazolo[1',5':4,5]pyrazino[2,1-a]isoquinoline





PHP030_1_Silica_4.6X250_MeOH_5-30%_6min

PHP030_1

3: Diode Array
Range: 1.865e+1




PHP030_1 197 (3.412)
1: Scan ES+
2.57e7



Chemical Formula: C₂₀H₂₀ClN₅O₂
Exact Mass: 397.13


14c: 1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)-N-(3,4-dimethoxyphenethyl)cyclohexanamine



PHP035_1_Silica_4.6X250_MeOH_5-30%_6min


PHP035_1

3: Diode Array
Range: 2.261e+1





PHP035_1

1: Scan ES+
420.25
3.10e7




PHP035_1 165 (2.857)

1: Scan ES+
6.88e7



Chemical Formula: C₂₁H₃₃N₅O₄
Exact Mass: 419.25


**4c: 2',3'-dimethoxy-5',6',13',13a'-tetrahydrospiro[cyclohexane-1,8'-tetrazolo
[1',5':4,5]pyrazino[2,1-a]isoquinoline]**



PHP039_1_Silica_4.6X250_MeOH_5-30%_6min



PHP039_1

3: Diode Array
Range: 8.24




PHP039_1 182 (3.152)

1: Scan ES+
8.14e7



Chemical Formula: C₁₉H₂₅N₅O₂
Exact Mass: 355.20


14d: N-(2-(1H-indol-3-yl)ethyl)-1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl) cyclohexanamine.



PHP080_1_Silica_4.6X250_MeOH_5-30%_6min


PHP080_1

3: Diode Array
Range: 8.213e+1



PHP080_1


2: Scan ES-
397.24
1.69e7




PHP080_1_Silica_4.6X250_MeOH_5-30%_6min

PHP080_1 206 (3.577)

2: Scan ES-
1.15e7




**4d: 7',12',12b',13'-tetrahydro-6'H-spiro[cyclohexane-1,4'-tetrazolo[1'',5'':4',5']
pyrazino[1',2':1,2]pyrido[3,4-b]indole]**



PHP083_1_Silica_4.6X250_MeOH_5-30%_6min


PHP083_1

3: Diode Array
Range: 7.866e+1



PHP083_1



2: Scan ES-
333.19
4.71e7



PHP083_1_Silica_4.6X250_MeOH_5-30%_6min

PHP083_1 192 (3.334)


2: Scan ES-
346e7



Chemical Formula: C₁₉H₂₂N₆

Exact Mass: 334.19


14e: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(4-nitrophenyl)methyl)-2-(1H-indol-3-yl)ethanamine



PHP071_1_Silica_4.6X250_MeOH_5-30%_6min


PHP071_1

3: Diode Array
Range: 1.512e+2





PHP071_1

1: Scan ES+
452.1
1.68e7





PHP071_1 227 (3.933)

1: Scan ES+
6.13e7



Chemical Formula: C₂₂H₂₅N₇O₄
Exact Mass: 451.20


4e: 4-(4-nitrophenyl)-4,6,7,12,12b,13-hexahydro-tetrazolo[1'',5'':4',5']pyrazino[1',2':1,2]pyrido[3,4-b]indole



PHP074_1_Silica_4.6X250_MeOH_5-30%_6min


PHP074_1

3: Diode Array
Range: 6.715



PHP074_1



2: Scan ES-
386.14
1.24e7



PHP074_1_Silica_4.6X250_MeOH_5-30%_6min


PHP074_1 219 (3.803)

2: Scan ES-
1.24e7



Chemical Formula: C₂₀H₁₇N₇O₂
Exact Mass: 387.14
Molecular Weight: 387.39


14f: N-(2-(1H-indol-3-yl)ethyl)-1-benzyl-4-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)piperidin-4-amine




PHP-085_r2_Col3_Sol1_20-40%_7min

PHP-085_r2

3: Diode Array
Range: 4.104e+1





PHP-085_r2



PHP-085_r2_Col3_Sol1_20-40%_7min


PHP-085_r2 137 (2.379) Cm (132:146)

2: Scan ES-
488
2.15e6



Chemical Formula: C₂₇H₃₅N₇O₂
Exact Mass: 489.29


**4f: 1-benzyl-7',12',12b',13'-tetrahydro-6'H-spiro[piperidine-4,4'-
tetrazolo[1'',5'':4',5']pyrazino[1',2':1,2]pyrido[3,4-b]indole]**



PHP-108_r1_Col3_Sol1_20-40%_7min


PHP-108_r1

3: Diode Array
Range: 1.616e+1



PHP-108_r1


1: Scan ES+
426
7.67e7




PHP-108_r1_Col3_Sol1_20-40%_7min

PHP-108_r1 154 (2.666) Cm (149:175)

1: Scan ES+
3.72e7




14g: N-((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methyl)-2-(1H-indol-3-yl)ethanamine



PHP084_1_Silica_4.6X250_MeOH_5-30%_6min


PHP084_1

3: Diode Array
Range: 6.344e+1



PHP084_1


2: Scan ES-
495.24
1.25e7




PHP084_1_Silica_4.6X250_MeOH_5-30%_6min

PHP084_1 238 (4.133)

2: Scan ES-
1.24e7




**4g: 4-(3,4,5-trimethoxyphenyl)-4,6,7,12,12b,13-hexahydro-tetrazolo[1'',5'':4',5']
pyrazino[1',2':1,2]pyrido[3,4-b]indole**



PHP087_1_Silica_4.6X250_MeOH_5-30%_6min


PHP087_1

3: Diode Array
Range: 4.828e+1



PHP087_1


2: Scan ES-
431.19
1.34e7





PHP087_1_Silica_4.6X250_MeOH_5-30%_6min

PHP087_1 232 (4.029)

2: Scan ES-
1.27e7




14h: methyl 2-((1-(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)cyclohexyl)amino)-3-(1H-indol-3-yl)propanoate




PHP054_1_Silica_4.6X250_MeOH_5-30%_6min
PHP054_1

3: Diode Array
Range: 7.421e+1





PHP054_1

2: Scan ES-
455.25
1.61e7





PHP054_1_Silica_4.6X250_MeOH_5-30%_6min
PHP054_1 201 (3.491)

2: Scan ES-
1.39e7




Chemical Formula: C₂₃H₃₂N₆O₄
Exact Mass: 456.25

**4h: methyl 7',12',12b',13'-tetrahydro-6'H-spiro[cyclohexane-1,4'-tetrazolo
[1'',5'':4',5']pyrazino[1',2':1,2]pyrido[3,4-b]indole]-6'-carboxylate**




PHP055_1_Silica_4.6X250_MeOH_5-30%_6min
PHP055_1

3: Diode Array
Range: 5.511e+1




PHP055_1

2: Scan ES-
391.2
2.72e7





PHP055_1_Silica_4.6X250_MeOH_5-30%_6min
PHP055_1 179 (3.108)

2: Scan ES-
1.39e7




14i: methyl 2-(((4-chlorophenyl)(1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)methyl)amino)-3-(1H-indol-3-yl)propanoate



PHP059_1_Silica_4.6X250_MeOH_5-30%_6min


PHP059_1

3: Diode Array
Range: 4.666e+1



PHP059_1


2: Scan ES-
497.18
2.08e7




PHP059_1_Silica_4.6X250_MeOH_5-30%_6min

PHP059_1 201 (3.490)

2: Scan ES-
1.17e7




**4i: methyl 4-(4-chlorophenyl)-4,6,7,12,12b,13-hexahydro-1H-tetrazolo[1',5'':4',5']
pyrazino[1',2':1,2]pyrido[3,4-b]indole-6-carboxylate**



PHP066_1_Silica_4.6X250_MeOH_5-30%_6min


PHP066_1

3: Diode Array
Range: 6.279e+1



PHP066_1


2: Scan ES-
433.13
1.48e7




PHP066_1_Silica_4.6X250_MeOH_5-30%_6min

PHP066_1 196 (3.404)

2: Scan ES-
1.02e7




14j: methyl 2-(((1-(2,2-dimethoxyethyl)-1H-tetrazol-5-yl)(phenyl)methyl)amino)-3-(1H-indol-3-yl)propanoate



PHP099_1_Silica_4.6X250_MeOH_5-30%_6min


PHP099_1

3: Diode Array
Range: 2.357e+



PHP099_1



2: Scan ES-
463.22
9.26e6



PHP099_1_Silica_4.6X250_MeOH_5-30%_6min



PHP099_1 209 (3.629)

2: Scan ES-
3.55e6



Chemical Formula:
 $C_{24}H_{28}N_6O_4$
Exact Mass: 464.22


4j: methyl 4-phenyl-4,6,7,12,12b,13-hexahydro-tetrazolo[1'',5'':4',5']pyrazino[1',2':1,2]pyrido[3,4-b]indole-6-carboxylate



PHP118_1_Silica_4.6X250_MeOH_5-30%_6min


PHP118_1

3: Diode Array
Range: 3.618e+1



PHP118_1

1: Scan ES+
401.17
2.49e7



PHP118_1 203 (3.517)

1: Scan ES+
2.41e7

